BR112017018312B1 - PI3K INHIBITOR SALTS, COMPOSITIONS INCLUDING THEM, THEIR USE, PROCESSES FOR THEIR PREPARATION AND METHOD FOR INHIBITING AN ACTIVITY OF A PI3K KINASE - Google Patents

Abstract

PI3K INHIBITOR SALTS AND PROCESSES FOR THEIR PREPARATION. The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor of phosphoinositide 3-kinase delta (PI3Kd), as well as a salt form and related intermediates thereof.

Description

[001] This application claims the benefit of Application Serial No. US 62/121,697, filed on February 27, 2015, which is incorporated herein, by reference, in its entirety.

TECHNICAL FIELD

[002] The present application provides process for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), as well as a salt form and intermediates related to it.

BACKGROUND

[003] Phosphoinositide 3-kinases (PI3Ks) belong to a large family of lipid signaling kinases that phosphorylate phosphoinositides at the D3 position of the inositol ring ( Cantley, Science, 2002, 296(5573):1655 to 1657 ). PI3Ks are divided into three classes (class I, II and III) according to their structure, regulation and substrate specificity. Class I PI3Ks, which include PI3Kα, PI3Kβ, PI3KY and PI3Kδ, are a family of dual-specific lipid and protein kinases that catalyze the phosphorylation of phosphatidylinosito-4,5-bisphosphate (PIP2) to phosphatidylinosito-3,4,5-trisphosphate (PIP3). PIP3 functions as a second messenger that controls numerous cellular processes including growth, survival, adhesion and migration. All four class I PI3K isoforms exist as heterodimers comprised of a catalytic subunit (p110) and a tightly associated regulatory subunit that controls their expression, activation, and subcellular localization. PI3Kα, PI3Kβ and PI3Kδ associate with a regulatory subunit known as p85 and are activated by growth factors and cytokines through a tyrosine kinase-dependent mechanism ( Jimenez, et al., J Biol Chem., 2002, 277(44): 41556 to 41562 ), while PI3KY associates with two regulatory subunits (p101 and p84 ) and its activation is triggered by the activation of G protein-coupled receptors ( Brock, et al., J Cell Biol., 2003, 160(1):89 to 99 ). PI3Kα and PI3Kβ are ubiquitously expressed. In contrast, PI3KY and PI3Kδ are predominantly expressed in leukocytes ( Vanhaesebroeck, et al., Trends Biochem Sci., 2005, 30(4):194 to 204 ).

[004] The differential tissue distribution of PI3K isoform factors in their distinct biological functions. Genetic ablation of either PI3Kα or PI3Kβ results in embryonic lethality, indicating that PI3Kα and PI3Kβ have essential, non-redundant functions, at least during development (Vanhaesebroeck, et al., 2005). In contrast, mice that lack PI3KY and PI3Kδ are viable, fertile and have a normal lifespan although they show an altered immune system. PI3KY deficiency leads to impaired recruitment of macrophages and neutrophils to sites of inflammation as well as impaired T-cell activation ( Sasaki, et al., Science, 2000, 287(5455):1040-1046 ). PI3Kδ-mutant mice have specific defects in B cell signaling that lead to impaired B cell development and reduced antibody responses after antigen stimulation ( Clayton, et al., J Exp Med. 2002, 196(6):753 to 763; Jou, et al., Mol Cell Biol. 2002, 22(24):8580 to 8591; Okkenhaug, et al., Science, 2002, 297(5583):1031 to 1034 ).

[005] The phenotypes of PI3KY and PI3Kδ-mutant mice suggest that these enzymes may play a role in inflammation and other immune-based diseases and this is confirmed in preclinical models. PI3KY-mutant mice are largely protected against disease in mouse models of rheumatoid arthritis (RA) and asthma ( Camps, et al., Nat Med. 2005, 11(9):936-943 ; Thomas, et al., Eur. J. Immunol. 2005, 35(4):1283-1291 ). Furthermore, treatment of wild-type mice with a selective PI3KY inhibitor has been shown to reduce glomerulonephritis and prolong survival in the MRL-lpr model of systemic lupus nephritis (SLE) and to suppress joint inflammation and damage in RA models (Barber, et al., Nat Med. 2005, 11(9):933-935; Camps, et al., 2005). Similarly, both PI3Kδ-mutant and wild-type mice treated with a selective PI3Kδ inhibitor have been shown to have attenuated allergic airway inflammation and hyperresponsiveness in a mouse model of asthma ( Ali, et al., Nature. 2004, 431(7011):1007-1011; Lee, et al., FASEB J. 2006, 20(3) ):455 to 465) and have attenuated disease in an RA model ( Randis, et al., Eur. J. Immunol., 2008, 38(5):1215 to 1224 ).

[006] B cell proliferation has been shown to play an important role in the development of inflammatory autoimmune diseases (Puri, Frontiers in Immunology (2012), 3(256), 1 to 16; Walsh, Kidney International (2007) 72, 676 to 682). For example, B cells support T cell autoreactivity, an important component of inflammatory autoimmune diseases. Once activated and matured, B cells can travel to sites of inflammation and recruit inflammatory cells or differentiate into plasmablasts. In this way, B-cell activity can be affected by targeting B-cell-stimulating cytokines, B-cell surface receptors, or through B-cell depletion. Rituximab—a chimeric mouse/human IgG1K monoclonal antibody directed against the B-cell surface receptor CD20—has been shown to deplete CD20+ B cells. The use of rituximab has been shown to be effective in the treatment of idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, or vasculitis. For example, treatment with rituximab has resulted in disease remission in patients suffering from systemic vasculitis (AASV) associated with antineutrophil cytoplasmic antibody (ANCA) with demonstrated peripheral B-cell depletion (Walsh, 2007; Lovric, Nephrol Dial Transplant (2009) 24: 179-185). Similarly, a complete response was reported in one-third to two-thirds of patients having mixed cryoglobulinemic vasculitis after treatment with rituximab, including patients who had a severe form of vasculitis that was resistant or intolerant of other treatments (Cacoub, Ann Rheum Dis 2008;67:283-287). Similarly, rituximab has been shown to be effective in treating patients with idiopathic thrombocytopenic purpura (or immune thrombocytopenic purpura) (Garvey, British Journal of Haematology, (2008) 141, 149 to 169; Godeau, Blood (2008), 112(4), 999 to 1004; Medeo, European Journal of Haematology, (2008) 81, 165 to 169) and autoimmune hemolytic anemia (Garvey, British Journal of Haematology, (2008) 141, 149 to 169).

[007] PI3Kδ signaling is tied to B cell survival, migration, and activation ( Puri, Frontiers in Immunology, 2012, 3(256), 1 to 16, pages 1 to 5; and Clayton, J Exp Med, 2002, 196(6):753 to 63). For example, PI3Kδ is required for B cell receptor-driven antigen-dependent B cell activation. By blocking B cell adhesion, survival, activation, and proliferation, inhibition of PI3Kδ can impair the ability of B cells to activate T cells, preventing their activation and reducing the secretion of autoantibodies and proinflammatory cytokines. Hence, by their ability to inhibit B cell activation, PI3Kδ inhibitors would be expected to treat B cell mediated diseases that were treatable by similar methods as rituximab B cell depletion. In fact, PI3Kδ inhibitors have been shown to be useful mouse models of various autoimmune diseases that are also treatable by rituximab such as arthritis (Puri (2012)). Additionally, innate type B cells, which are linked to autoimmunity and are sensitive to PI3Kδ activity, such as MZ and B-1 cells, are almost absent in mice lacking the p110δ gene (Puri (2012). PI3Kδ inhibitors can reduce the trafficking of and activation of MZ and B-1 cells, which are implicated in autoimmune diseases.

[008] In addition to their potential role in inflammatory diseases, all four class I PI3K isoforms may play a role in cancer. The gene encoding p110α is frequently mutated in common cancers, including breast, prostate, colon, and endometrial ( Samuels, et al., Science, 2004, 304(5670):554 ; Samuels, et al., Curr Opin Oncol. 2006, 18(1):77-82 ). Eighty percent of these mutations are represented by one of three amino acid substitutions in the helical or kinase domains of the enzyme and lead to an upregulation of kinase activity resulting in oncogenic transformation in cell culture and animal models ( Kang, et al., Proc Natl Acad Sci U S A. 2005, 102(3): 802 to 807 ; Bader, et al., Proc Natl Acad Sci U S A. 2006, 103(5):1475 to 1479). None of these mutations have been identified in the other PI3K isoforms, although there is evidence that they may contribute to the development and progression of malignancies. Consistent overexpression of PI3Kδ is seen in acute myeloblastic leukemia ( Sujobert, et al., Blood, 2005, 106(3):1063-1066 ) and PI3Kδ inhibitors can prevent the growth of leukemic cells ( Billettet, et al., Oncogene. 2006, 25(50):6648-6659 ). Elevated expression of PI3KY is seen in chronic myeloid leukemia ( Hickey, et al., J Biol. Chem. 2006, 281(5):2441 to 2450 ). Alterations in the expression of PI3Kβ, PI3KY and PI3Kδ have also been observed in brain, colon and bladder cancers ( Benistant, et al., Oncogene, 2000, 19(44):5083 to 5090; Mizoguchi, et al., Brain Pathol. 2004, 14(4):372 to 377; Knobbe, et al., Neuropathol Appl Neuro biol., 2005, 31(5):486 to 490 ). Additionally, all these isoforms were shown to be oncogenic in cell culture (Kang, et al., 2006).

[009] For these reasons, there is a need to develop new PI3K inhibitors that can be used in inflammatory disorders, autoimmune diseases and cancer. This invention addresses this need and others.

SUMMARY

[0010] This application provides processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt thereof, which is useful as a PI3Kδ inhibitor.

[0011] The present application further provides a hydrochloric acid salt of the compound of Formula I.

[0012] The present application also provides pharmaceutical compositions comprising a hydrochloric acid salt described herein and a pharmaceutically acceptable carrier.

[0013] The present application further provides methods of inhibiting an activity of a PI3K kinase, comprising bringing the kinase into contact with the hydrochloric acid salt of the compound of Formula I.

[0014] The present application also provides methods of treating a disease in a patient, wherein said disease is associated with abnormal expression or activity of a PI3K kinase, comprising administering to said patient a therapeutically effective amount of the hydrochloric acid salt of the compound of Formula I.

[0015] The present application further provides the hydrochloric acid salt of the compound of Formula I for use in any of the methods described herein.

[0016] The present application further provides the use of the hydrochloric acid salt of the compound of Formula I for the manufacture of a medicament for use in any of the methods described herein.

[0017] The present application also provides a process for preparing the hydrochloric acid salt of the compound of Formula I comprising reacting a compound of Formula I:

[0018] with hydrochloric acid to form said salt.

[0019] The present application additionally provides a process for preparing a compound of Formula I comprising reacting a compound of Formula XVI:

[0020] withformamidine acetate to form said compound of Formula I:

[0021] This application also provides a compound of Formula XIV:

[0022] or a pharmaceutically acceptable salt thereof.

[0023] The present application also provides a compound of Formula XV:

[0024] or a pharmaceutically acceptable salt thereof.

[0025] The present application additionally provides a compound of Formula XVI:

[0026] or a pharmaceutically acceptable salt thereof.

[0027] This application also provides a compound of Formula XIX:

[0028] or a pharmaceutically acceptable salt thereof.

[0029] The present application also provides a compound of Formula XX:

[0030] or a pharmaceutically acceptable salt thereof.

[0031] The present application additionally provides a compound of Formula XXI:

[0032] or a pharmaceutically acceptable salt thereof.

DESCRIPTION OF FIGURES

[0033] Figure 1 shows a representative DSC thermogram of the salt from Example 3.

[0034] Figure 2 shows representative TGA data for the salt of Example 3.

[0035] Figure 3 shows a representative XRPD pattern for the salt of Example 3.

DETAILED DESCRIPTION COMPOUNDS AND SALTS

[0036] This application provides processes for preparing a compound of Formula I:

[0037] or a pharmaceutically acceptable salt thereof, which is useful as a PI3Kδ inhibitor, wherein Et is ethyl.

[0038] The present application further provides a salt of the compound of Formula I.

[0039] Accordingly, in some embodiments, the present application provides 4-(3-(1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloric acid salt. In some embodiments, the present application provides (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloric acid salt. In some embodiments, the salt is a 1:1 stoichiometric ratio of (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one and hydrochloric acid.

[0040] Different forms of the same substance have different bulk properties related, for example, to hygroscopicity, solubility, stability and the like. Forms with high melting points often have good thermodynamic stability which is advantageous in extending the shelf life of drug formulations containing the solid form. Forms with lower melting points are often less thermodynamically stable, but are advantageous in that they have increased water solubility, translating to increased drug bioavailability. Forms that are weakly hygroscopic are desirable for their stability to heat and moisture and are resistant to degradation during long-term storage.

[0041] In some embodiments, the hydrochloric acid salt of the compound of Formula I provided herein is crystalline. As used herein, "crystalline" or "crystalline form" is intended to refer to a certain lattice configuration of a crystalline substance. Different crystalline forms of the same substance typically have different crystalline lattices (eg, unit cells) which are attributed to different physical properties that are characteristic of each of the crystalline forms. In some cases, different grid configurations have different water or solvent content.

[0042] The different salt forms can be identified by solid state characterization methods such as X-ray powder diffraction (XRPD). Other characterization methods such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS) and the like further help to identify shape as well as help to determine stability and solvent/water content.

[0043] An XRPD pattern of reflections (peaks) is typically considered a fingerprint of a particular crystalline form. It is well known that the relative intensities of XRPD peaks can vary widely depending on, among others, the sample preparation technique, the crystal size distribution, the various filters used, the sample assembly procedure and the particular instrument employed. In some cases, new peaks may be observed or existing peaks may disappear, depending on instrument type or settings. As used herein, the term "peak" refers to a reflection having a relative height/intensity of at least about 4% of the maximum peak height/intensity. Furthermore, instrument variation and other factors can affect 2-theta values. As such, peak assignments, such as those reported herein, can vary by plus or minus about 0.2° (2-theta) and the term "substantially" and "about" as used in the context of XRPD herein is intended to encompass the ranges mentioned above.

[0044] In some embodiments, the hydrochloric acid salt of the compound of Formula I has at least one XRPD peak, in 2-theta terms, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2° and about 32.8°. In some embodiments, the hydrochloric acid salt of the compound of Formula I has at least two XRPD peaks, in 2-theta terms, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2° and about 32.8°. In some embodiments, the hydrochloric acid salt of the compound of Formula I has at least three XRPD peaks, in 2-theta terms, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2° and about 32.8°. In some embodiments, the hydrochloric acid salt of the compound of Formula I has at least four XRPD peaks, in 2-theta terms, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2° and about 32.8°. In some embodiments, the hydrochloric acid salt of the compound of Formula I has at least five XRPD peaks, in 2-theta terms, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2° and about 32.8°. In some embodiments, the hydrochloric acid salt of the compound of Formula I has an XRPD profile substantially as shown in Figure 3.

[0045] Likewise, temperature readings in conjunction with DSC, TGA or other thermal experiments can vary by about ±3 °C depending on the instrument, particular settings, sample preparation, etc. Accordingly, a crystalline form reported herein having a DSC thermogram "substantially" as shown in any of the Figures or the term "about" is intended to accommodate such variation. In some embodiments, the hydrochloric acid salt of the compound of Formula I has a DSC thermogram having an endothermic peak at about 207°C. In some embodiments, the hydrochloric acid salt of the compound of Formula I has a DSC thermogram substantially as shown in Figure 1. In some embodiments, the hydrochloric acid salt of the compound of Formula I has a TGA thermogram substantially as shown in Figure 2.

[0046] In some embodiments, the salts and compounds described herein (e.g., the compound of Formula I or the hydrochloric acid salt of the compound of Formula I) are substantially isolated. By "substantially isolated" is meant that the salt or compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation may include, for example, a composition enriched in the salts described herein. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the salts described herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

INTERMEDIARIES

[0047] The present application further provides intermediates that are useful in preparing the compound of Formula I.

[0048] Accordingly, in some embodiments, the present application provides a compound of Formula XIV:

[0049] or a pharmaceutically acceptable salt thereof.

[0050] This application also provides a compound of Formula XV:

[0051] or a pharmaceutically acceptable salt thereof.

[0052] This application also provides a compound of Formula XVI:

[0053] or a pharmaceutically acceptable salt thereof.

[0054] This application also provides a compound of Formula XIX:

[0055] or a pharmaceutically acceptable salt thereof.

[0056] This application also provides a compound of Formula XX:

[0057] or a pharmaceutically acceptable salt thereof.

[0058] This application also provides a compound of Formula XXI:

[0059] a pharmaceutically acceptable salt thereof.

LAW SUIT

[0060] This application also provides a process for preparing a salt of Formula I:

[0061] In some embodiments, the process comprises reacting a compound of Formula I:

[0062] with hydrochloric acid to form said salt.

[0063] In some embodiments, said hydrochloric acid is 1M aqueous hydrochloric acid.

[0064] In some embodiments, about 3.3 to about 3.7 equivalents of hydrochloric acid are used based on 1 equivalent of the compound of Formula I.

[0065] In some embodiments, said reaction is carried out at a temperature of about 45°C to about 55°C.

[0066] In some modalities, the process comprises:

[0067] add hydrochloric acid to the compound of Formula I at room temperature to form an aqueous slurry;

[0068] heating said aqueous slurry to a temperature of about 45°C to about 55°C to form a solution; It is

[0069] cooling the solution to a temperature of about 0°C to about 5°C to crystallize said salt.

[0070] In some embodiments, the process comprises reacting a compound of Formula XVI:

[0071] withformamidine acetate to form a compound of Formula I:

[0072] In some embodiments, said reaction of the compound of Formula XVI withformamidine acetate is conducted in a solvent component comprising 1,2-ethanediol.

[0073] In some embodiments, said reaction of the compound of Formula XVI withformamidine acetate is carried out at a temperature of about 100°C to about 105°C.

[0074] In some embodiments, about 8 to about 10 equivalents offormamidine acetate are used based on 1 equivalent of the compound of Formula XVI.

[0075] In some embodiments, the process further comprises preparing the Formula XVI compound by a process comprising reacting a Formula XV compound:

[0076] with (1-ethoxyethylidene)malononitrile in the presence of a tertiary amine.

[0077] In some embodiments, said tertiary amine is N-methylpyrrolidinone.

[0078] In some embodiments, said reaction of the compound of Formula XV with (1-ethoxyethylidene)malononitrile is performed at about room temperature.

[0079] In some embodiments, the process further comprises preparing the compound of Formula XV by a process comprising reacting a compound of Formula XIV-a:

[0080] with hydrazine in the presence of a tertiary amine, where P1 is C1-6 alkylsulfonyl.

[0081] In some embodiments, said tertiary amine is N-methylpyrrolidinone.

[0082] In some embodiments, said reaction of the compound of Formula XIV-a with hydrazine is carried out at a temperature of from about 35°C to about 60°C.

[0083] In some embodiments, said reaction of the compound of Formula XIV-a with hydrazine is conducted in a solvent component comprising dichloromethane.

[0084] In some embodiments, P1 is methanesulfonyl group.

[0085] In some embodiments, the process further comprises preparing the compound of Formula XIV by a process comprising reacting a compound of Formula XIII:

[0086] with C1-6 alkylsulfonyl halide in the presence of a tertiary amine.

[0087] In some embodiments, said C1-6 alkylsulfonyl halide is methanesulfonyl chloride.

[0088] In some embodiments, said tertiary amine is N,N-diisopropylethylamine.

[0089] In some embodiments, about 1.1 to about 1.5 equivalent of alkylsulfonyl halide is used based on 1 equivalent of the compound of Formula XIII.

[0090] In some embodiments, said reaction of said compound of Formula XIII with C1-6 alkylsulfonyl halide is carried out at a temperature of about -10°C to about 5°C.

[0091] In some embodiments, said reaction of said compound of Formula XIII with C1-6 alkylsulfonyl halide is carried out in a solvent component comprising dichloromethane.

[0092] In some embodiments, the steps of: (i) reacting said compound of Formula XIII with C1-6 alkylsulfonyl halide; (ii) reacting said compound of Formula XIV-a with hydrazine in the presence of a tertiary amine to form a compound of Formula XV; and (iii) reacting said Formula XV compound with Formamidine acetate to form a Formula XVI compound are conducted in the same pot without isolation of the Formula XIV-a compound or the Formula XV compound.

[0093] In some embodiments, the process further comprises preparing the compound of Formula XVI by a process comprising reacting a salt of Formula XV-a:

[0094] with (1-ethoxyethylidene)malononitrile in the presence of a tertiary amine, where TsOH is p-toluenesulfonic acid.

[0095] In some embodiments, said tertiary amine is N,N-diisopropylethylamine.

[0096] In some embodiments, said reaction of a salt of Formula XV-a with (1-ethoxyethylidene)malononitrile is performed at about room temperature.

[0097] In some embodiments, about 1.3 to about 1.6 equivalent of (1-ethoxyethylidene)malononitrile is used based on 1 equivalent of the salt of Formula XV-a.

[0098] In some embodiments, said reaction of the salt of Formula XV-a with (1-ethoxyethylidene)malononitrile is conducted in a solvent component comprising ethanol.

[0099] In some embodiments, the process further comprises preparing the Formula XV-a salt by a process comprising reacting a Formula XXI compound:

[00100] with p-toluenesulfonic acid, where Boc is tert-butoxycarbonyl.

[00101] In some embodiments, said p-toluenesulfonic acid is p-toluenesulfonic acid monohydrate.

[00102] In some embodiments, about 1.3 to about 1.6 equivalent of p-toluenesulfonic acid is used based on 1 equivalent of the compound of Formula XXI.

[00103] In some embodiments, said reaction of said compound of Formula XXI with p-toluenesulfonic acid is carried out at a temperature of from about 45°C to about 65°C.

[00104] In some embodiments, the reaction of said compound of Formula XXI with p-toluenesulfonic acid is conducted in a solvent component comprising ethanol.

[00105] In some embodiments, the steps of: (i) reacting said compound of Formula XXI with p-toluenesulfonic acid to form a salt of Formula XV-a; and (ii) reacting said Formula XV-a salt with (1-ethoxyethylidene)malononitrile are conducted in the same pot without isolation of the Formula XV-a salt.

[00106] In some embodiments, the process further comprises preparing the compound of Formula XXI by a process comprising reacting a compound of Formula XX:

[00107] with hydrogen gas in the presence of one or more independently selected hydrogenation catalysts, where Boc is tert-butoxycarbonyl.

[00108] In some embodiments, said reaction of the compound of Formula XX with hydrogen gas is carried out in the presence of two independently selected hydrogenation catalysts.

[00109] In some embodiments, one hydrogenation catalyst is bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate and the other is (R)-(-)-1-{(S)-2-[bis(4-trifluoromethylphenyl)phosphine]ferrocenyl}ethyl-di-t-butylphosphine.

[00110] In some embodiments, about 13.5 to about 14.5 equivalents of bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate are used based on 1 equivalent of the compound of Formula XX.

[00111] In some embodiments, about 12 to about 13 equivalents of (R)-(-)-1-{(S)-2-[bis(4-trifluoromethylphenyl)phosphine]ferrocenyl}ethyl-di-t-butylphosphine are used based on 1 equivalent of the compound of Formula XX.

[00112] In some embodiments, said reaction of the compound of Formula XX with hydrogen gas is carried out at about room temperature.

[00113] In some embodiments, said reaction of the compound of Formula XX with hydrogen gas is conducted in a solvent component comprising methanol.

[00114] In some embodiments, the process further comprises preparing the compound of Formula XX by a process comprising reacting a compound of Formula XIX:

[00115] with t-butyl carbazate.

[00116] In some embodiments, said reaction of the compound of Formula XIX with t-butyl carbazate is carried out at a temperature of about 60°C to about 70°C.

[00117] In some embodiments, said reaction of the compound of Formula XIX with t-butyl carbazate is conducted in a solvent component comprising methanol.

[00118] In some embodiments, the process further comprises preparing the compound of Formula XIX by a process comprising oxidizing a compound of Formula XIII-a:

[00119] in the presence of an oxidizing agent.

[00120] In some embodiments, said oxidizing agent is Dess-Martin periodinane.

[00121] In some embodiments, about 1.2 to about 1.7 equivalent of said oxidizing agent is used based on 1 equivalent of the compound of Formula XIII-a.

[00122] In some embodiments, said oxidation of the compound of Formula XIII-a is carried out at about room temperature.

[00123] In some embodiments, said oxidation of the compound of Formula XIII-a is conducted in a solvent component comprising dichloromethane.

[00124] In some embodiments, said compound of Formula XIII is prepared by a process comprising heating a compound of Formula XII:

[00125] in the presence of a solvent component.

[00126] In some embodiments, said heating is carried out at a temperature of about 95°C to about 105°C.

[00127] In some embodiments, said solvent component comprises 1,4-dioxane.

[00128] In some embodiments, said solvent component comprises toluene.

[00129] In some embodiments, said solvent component comprises 1,4-dioxane and toluene.

[00130] In some embodiments, said compound of Formula XII is prepared by a process comprising reacting a compound of Formula XI:

[00131] in the presence of a strong base.

[00132] In some embodiments, said strong base is sodium hydroxide.

[00133] In some embodiments, said strong base is 1M aqueous sodium hydroxide.

[00134] In some embodiments, said reaction is carried out at about room temperature.

[00135] In some embodiments, said compound of Formula XI is prepared by a process comprising reacting a compound of Formula X:

[00136] with hydrogen gas in the presence of Raney nickel.

[00137] In some embodiments, said reaction is carried out at a temperature of about 50°C to about 70°C.

[00138] In some embodiments, said compound of Formula X is prepared by a process comprising reacting a compound of Formula IX:

[00139] in the presence of boron trifluoride etherate, (3aS)-1-methyl-3,3-diphenyltetrahydro-3H-pyrrolo[1,2-c][1,3,2]oxazaborol ((S)-MeCBS) catalyst and a borane complex.

[00140] In some embodiments, about 0.03 to about 0.07 equivalent of boron trifluoride etherate is used based on 1 equivalent of the compound of Formula IX.

[00141] In some embodiments, about 0.05 to about 0.15 equivalent of (3aS)-1-methyl-3,3-diphenyltetrahydro-3H-pyrrolo[1,2-c][1,3,2]oxazaborol ((S)-MeCBS) catalyst is used based on 1 equivalent of the compound of Formula IX.

[00142] In some embodiments, said borane complex is borane-THF complex at 1.0 M in THF.

[00143] In some embodiments, about 0.9 to about 1.1 equivalents of borane complex is used based on 1 equivalent of the compound of Formula IX.

[00144] In some embodiments, said reaction is carried out at about room temperature.

[00145] In some embodiments, said compound of Formula IX is prepared by a process comprising reacting a compound of Formula VIII:

[00146] with iodine in the presence of a solvent component.

[00147] In some embodiments, said solvent component comprises acetone.

[00148] In some embodiments, about 0.75 to about 1.25 equivalent of iodine is used based on 1 equivalent of the compound of Formula VIII.

[00149] In some embodiments, said Formula VIII compound is prepared by a process comprising reacting a Formula VII compound:

[00150] with dimethyl malonate in the presence of a catalyst.

[00151] In some embodiments, said catalyst is (1S,2S)-N,N'-dibenzylcyclohexane-1,2-dibromoniquel-diamine (Evans Catalyst).

[00152] In some embodiments, about 1.1 to about 1.3 equivalent of dimethyl malonate is used based on 1 equivalent of the compound of Formula VII.

[00153] In some embodiments, about 0.02 to about 0.03 equivalent of transition metal catalyst is used based on 1 equivalent of the compound of Formula VII.

[00154] In some embodiments, said compound of Formula VII is prepared by a process comprising reacting a compound of Formula VI:

[00155] with nitromethane in the presence of an organic acid to form a first mixture.

[00156] In some embodiments, said organic acid is glacial acetic acid.

[00157] In some embodiments, about 9.5 to about 10.5 equivalents of nitromethane are used based on 1 equivalent of the compound of Formula VI.

[00158] In some embodiments, said reaction further comprises adding an amine base to said first mixture to form a second mixture.

[00159] In some embodiments, said amine base is benzylamine.

[00160] In some embodiments, about 0.2 to about 0.3 equivalent of amine base is used based on 1 equivalent of the compound of Formula VI.

[00161] In some embodiments, said second mixture is heated to about 55°C to about 65°C.

[00162] In some embodiments, said Formula VI compound is prepared by a process comprising reacting a Formula V compound:

[00163] with a (C1-4 alkyl)magnesium halide complex to form a first mixture.

[00164] In some embodiments, said (C1-4 alkyl)magnesium halide complex is 1.3 M isopropylmagnesium lithium chloride complex.

[00165] In some embodiments, about 1.1 to about 1.3 equivalent of said (C1-4 alkyl)magnesium halide complex is used based on 1 equivalent of the compound of Formula V.

[00166] In some embodiments, said reaction further comprises adding N-formylmorpholine to said first mixture to form a second mixture.

[00167] In some embodiments, about 1.8 to about 2.2 equivalents of N-formylmorpholine are used based on 1 equivalent of the compound of Formula V.

[00168] In some embodiments, said reaction is carried out at a temperature of about -5°C to about 10°C.

[00169] In some embodiments, said compound of Formula V is prepared according to procedures described in Publication No. U.S. 2013-0059835Al.

[00170] In some embodiments, said compound of Formula VI is prepared by a process comprising reacting a compound of Formula Va:

[00171] with N,N-dimethylformamide in the presence of lithium diisopropylamide.

[00172] In some embodiments, said lithium diisopropylamide is prepared by reacting N,N-diisopropylamine in the presence of n-butyllithium.

[00173] In some embodiments, said lithium diisopropylamide is prepared at a temperature of about -75°C to about 5°C.

[00174] In some ways:

[00175] (ii) said compound of Formula V-a is reacted with lithium diisopropylamide to form a first mixture; It is

[00176] (ii) N,N-dimethylformamide is added to said first mixture to form a second mixture.

[00177] In some embodiments, about 1.2 to about 1.3 equivalent of amine base is used based on 1 equivalent of the compound of Formula V-a.

[00178] In some embodiments, about 1.4 to about 1.6 equivalent of N,N-dimethylformamide is used based on 1 equivalent of the compound of Formula V-a.

[00179] In some embodiments, said compound of Formula Va is prepared by a process comprising reacting a compound of Formula IV-a:

[00180] with 1,2-ethanediol in the presence of p-toluenesulfonic acid.

[00181] In some embodiments, said p-toluenesulfonic acid is p-toluenesulfonic acid monohydrate.

[00182] In some embodiments, about 2.2 to about 2.7 equivalents of 1,2-ethanediol are used based on 1 equivalent of the compound of Formula IV-a.

[00183] In some embodiments, about 0.05 to about 0.1 equivalent of p-toluenesulfonic acid is used based on 1 equivalent of the compound of Formula IV-a.

[00184] In some embodiments, said reaction is carried out at about reflux.

[00185] In some embodiments, said compound of Formula IV-a is prepared by a process comprising reacting a compound of Formula II:

[00186] with CH2CH2-X1 in the presence of an alkali metal carbonate base, wherein:

[00187] X1 is halide.

[00188] In some embodiments, X1 is iodide.

[00189] In some embodiments, said alkali metal carbonate base is potassium carbonate.

[00190] In some embodiments, about 1.1 to about 1.3 equivalent of CH2CH2-X1 is used based on 1 equivalent of the compound of Formula II.

[00191] In some embodiments, about 1.8 to about 2.2 equivalents of alkali metal carbonate base are used based on 1 equivalent of the compound of Formula II.

[00192] In some embodiments, said reaction is carried out at about 55°C to about 65°C.

[00193] In some embodiments, said compound of Formula II is prepared according to procedures described in Publication No. U.S. 2013-0059835Al.

[00194] It is understood that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment (although it is envisaged that the embodiments are combined as if written in multiple dependent ways). In contrast, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination.

[00195] The salts and compounds described herein may be asymmetric (e.g., having one or more stereocenters). If no stereochemistry is indicated, then all stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated by structure or name. Salts and compounds of the present application which contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms of optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds and the like may also be present salts in the salts and compounds described herein and all said stable isomers are contemplated in the present application. Cis and trans geometric isomers of the salts and compounds of the present application are described and may be isolated as a mixture of isomers or as separate isomeric forms.

[00196] The resolution of racemic mixtures of salts and compounds can be performed by any of a number of methods known in the art. An exemplary method includes fractional recrystallization using a chiral resolving acid which is an optically active salt forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids, such as e-camphorsulfonic acid. Other suitable resolving agents for fractional crystallization methods include stereoisomerically pure forms of an α-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.

[00197] Resolution of racemic mixtures can also be performed by elution on a column packed with an optically active resolving agent (eg, dinitrobenzoylphenylglycine). A suitable eluting solvent composition can be determined by one skilled in the art.

[00198] Salts and compounds of the invention may also include all isotopes of atoms occurring in the intermediates or salts or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, hydrogen isotopes include tritium and deuterium.

[00199] In some embodiments, the compounds or salts can be found together with other substances such as water and solvents (eg, hydrates and solvates) or can be isolated.

[00200] In some embodiments, the compounds described herein, or salts thereof (e.g., the hydrochloric acid salt of the compound of Formula I), are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation may include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or a salt thereof. Methods for isolating compounds and their salts are routine in the art.

[00201] The expression "pharmaceutically acceptable" is used in this document to refer to those compounds, materials, compositions, and/or dosage forms that are contained within the scope of the medical judgment of the opinion, suitable for use in contact with the tissues of human subjects and animal subjects without excess toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[00202] As will be appreciated, the compounds provided herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of a number of possible synthetic routes. The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (eg, 1H or 13C), infrared spectroscopy, or spectrophotometry (eg, UV-visible); or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC) or other related techniques.

[00203] As used herein, the term "react" is used as known in the art and generally refers to the bridging of chemical reagents in such a way as to allow their interaction at the molecular level to achieve a chemical or physical transformation. In some embodiments, the reaction involves two reagents, where one or more equivalents of the second reagent are used relative to the first reagent. The reaction steps of the processes described herein can be conducted for a period and under suitable conditions to prepare the identified product.

[00204] The reactions of the processes described in this document can be performed in suitable solvents that can be readily selected by one skilled in the art of organic synthesis. Suitable solvents can be substantially unreactive with the starting materials (reagents), intermediates, or products at the temperatures at which the reactions are carried out, for example, temperatures that can range from the freezing temperature of the solvent to the boiling temperature of the solvent. A given reaction can be performed in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.

[00205] Suitable solvents may include halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, butyl chloride, dichloromethane, tetrachloroethylene, trichloroethylene, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1-dichloroethane, 2-chloro propane, 1,2-dichloroethane, 1,2-dibromoethane, hexafluorobenzene, 1,2,4-trichlorobenzene, 1,2-dichlorobenzene, chlorobenzene, fluorobenzene, mixtures thereof and the like.

[00206] Suitable ether solvents include: dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, mixtures of the same and similar.

[00207] Suitable protic solvents may include, by way of example and without limitation, water, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1-propanol, 2-propanol, 2-methoxyethanol, 1-butanol, 2-butanol, i-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-, 2-, or 3-pentanol, neopentyl alcohol, t-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol or glycerol.

[00208] Suitable aprotic solvents may include, by way of example and without limitation, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyr rolidinone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile, dimethyl sulfoxide, propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, ethyl methyl ketone, ethyl acetate, sulfolane, N,N-dimethylpropionamide, tetramethylurea, nitromethane, nitrobenzene or hexamethylphosphoramide.

[00209] Suitable hydrocarbon-based solvents include benzene, cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o-, or p-xylene, octane, indane, nonane, or naphthalene.

[00210] The reactions of the processes described in this document can be performed at appropriate temperatures that can be readily determined by one skilled in the art. Reaction temperatures will depend, for example, on the melting and boiling points of the reagents and the solvent, if present; the thermodynamics of the reaction (eg, vigorously exothermic reactions may need to be run at reduced temperatures); and the kinetics of the reaction (for example, a high activation energy barrier may need elevated temperatures).

[00211] The expressions "ambient temperature" and "ambient temperature" or "ta", as used herein, are understood in the art and refer, in general, to a temperature, for example, a reaction temperature, which is about the temperature of the environment in which the reaction is carried out, for example, a temperature of about 20°C to about 30°C.

[00212] The reactions of the processes described in this document can be performed in air or under an inert atmosphere. Typically, reactions containing reactants or products that are substantially reactive with air can be performed using air-sensitive synthetic techniques that are well known to the skilled person.

METHODS OF USE

[00213] The salts and compounds of the invention can modulate activity of one or more of several kinases including, for example, phosphoinositide 3-kinases (PI3Ks). The term "modular" is intended to refer to an ability to increase or decrease the activity of one or more members of the PI3K family. Accordingly, the salts and compounds of the invention can be used in methods of modulating a PI3K by contacting the PI3K with any one or more of the salts, compounds or compositions described herein. In some embodiments, salts and compounds of the present application can act as inhibitors of one or more PI3Ks. In additional embodiments, salts and compounds of the invention can be used to modulate activity of a PI3K in an individual in need of receptor modulation by administering a modulating amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. In some embodiments, to modulate is to inhibit.

[00214] Given that cancer cell growth and survival are impacted by multiple signaling pathways, the present application is useful for treating disease states characterized by drug-resistant kinase mutants. Furthermore, different kinase inhibitors, exhibiting different preferences in the kinases they modulate activities, can be used in combination. This approach could prove highly effective in treating disease states by targeting multiple signaling pathways, reducing the likelihood of drug resistance emerging in a cell, and reducing the toxicity of disease treatments.

[00215] Kinases to which the present salts and compounds bind and/or modulate (e.g., inhibit) include any member of the PI3K family. In some embodiments, the PI3K is PI3Kα, PI3Kβ, PI3Kδ or PI3KY. In some embodiments, the PI3K is PI3Kδ or PI3KY. In some embodiments, the PI3K is PI3Kδ. In some embodiments, PI3K is PI3KY. In some embodiments, the PI3K includes a mutation. A mutation can be a substitution of one amino acid for another, or a deletion of one or more amino acids. In such embodiments, the mutation may be present in the PI3K kinase domain.

[00216] In some embodiments, more than one salt or compound of the invention is used to inhibit the activity of a kinase (e.g., PI3Kδ or PI3KY).

[00217] In some embodiments, more than one salt or compound of the invention is used to inhibit more than one kinase, such as at least two kinases (e.g., PI3Kδ and PI3Ky).

[00218] In some embodiments, one or more of the salts or compounds are used in combination with another kinase inhibitor to inhibit the activity of a kinase (e.g., PI3Kδ or PI3Ky).

[00219] In some embodiments, one or more of the salts or compounds are used in combination with another kinase inhibitor to inhibit the activities of more than one kinase (e.g., PI3Kδ or PI3Ky), such as at least two kinases.

[00220] The salts and compounds of the invention can be selective. By "selective" is meant that the compound binds or inhibits a kinase with greater affinity or potency, respectively, compared to the at least one other kinase. In some embodiments, the salts and compounds of the invention are selective inhibitors of PI3Kδ or PI3Ky over PI3Kα and/or PI3Kβ. In some embodiments, salts and compounds of the invention are selective inhibitors of PI3Kδ (e.g., with respect to PI3Kα, PI3Kβ, and PI3Ky). In some embodiments, salts and compounds of the invention are selective inhibitors of PI3Kδ (e.g., with respect to PI3Kα, PI3Kβ, and PI3Ky). In some embodiments, the selectivity can be at least about 2 times, 5 times, 10 times, at least about 20 times, at least about 50 times, at least about 100 times, at least about 200 times, at least about 500 times, or at least about 1000 times. Selectivity can be measured by methods routine in the art. In some embodiments, selectivity can be tested on the Km ATP concentration of each enzyme. In some embodiments, the selectivity of salts and compounds of the invention can be determined by cellular assays associated with particular PI3K kinase activity.

[00221] Another aspect of the present application pertains to methods of treating a kinase associated disease or disorder (such as PI3K) in an individual (e.g. patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of one or more salts or compounds of the present application or a pharmaceutical composition thereof. A PI3K-associated disease can include any disease, disorder or condition that is directly or indirectly linked to PI3K expression or activity, including overexpression and/or abnormal levels of activity. In some embodiments, the disease can be linked to Akt (protein kinase B), mammalian target of rapamycin (mTOR), or phosphoinositide-dependent kinase 1 (PDK1). In some embodiments, mTOR-related disease can be inflammation, atherosclerosis, psoriasis, restenosis, benign prostatic hypertrophy, bone disorders, pancreatitis, angiogenesis, diabetic retinopathy, atherosclerosis, arthritis, immune disorders, kidney disease, or cancer. A PI3K-associated disease can also include any disease, disorder or condition that can be prevented, improved or cured by modulating PI3K activity. In some embodiments, the disease is characterized by abnormal PI3K activity. In some embodiments, the disease is characterized by mutant PI3K. In such embodiments, the mutation may be present in the PI3K kinase domain.

[00222] Examples of PI3K-associated diseases include immune-based diseases involving the system including, for example, rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus or inflammation related to any of the above.

[00223] Additional examples of PI3K-associated diseases include cancers such as breast, prostate, colon, endometrial, brain, bladder, skin, uterine, ovarian, lung, pancreatic, renal, gastric, or hematologic cancer.

[00224] Additional examples of diseases associated with PI3K include lung diseases such as acute lung injury (ALI) and adult respiratory distress syndrome (ARDS).

[00225] Additional examples of diseases associated with PI3K include osteoarthritis, restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, inflammation, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, myasthenia gravis, multiple sclerosis or Sjogren's syndrome and the like.

[00226] Additional examples of PI3K-associated diseases include idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, membranous nephropathy, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), hairy cell leukemia, mantle cell lymphoma, Burkitt's lymphoma , small lymphocytic lymphoma, follicular lymphoma, lymphoplasmic lymphoma, extranodal marginal zone lymphoma, diffuse large B-cell lymphoma of the B-cell-activated type (ABC), or diffuse large B-cell lymphoma of central germinal B-cell (GBC).

[00227] In some embodiments, the disease is selected from idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, autoimmune hemolytic anemia (AIHA), membranous nephropathy, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), hairy cell leukemia, mantle cell lymphoma, Burkitt's lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasmic lymphoma, extranodal marginal zone lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, mucosal associated lymphoma (MALT), B-cell lymphoma, large mediastinal (thymic) B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma nica, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (also known as asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), and B-cell lymphoma.

[00228] In some embodiments, the method is a method of treating idiopathic thrombocytopenic purpura (ITP) selected from relapsed ITP and refractory ITP.

[00229] In some embodiments, the method is a method of treating selected vasculitis of Behçet's disease, Cogan's syndrome, giant cell arthritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemic vasculitis (induced by hepatitis C virus (HPC) or essential), Henoch-Schonlein purpura (HSP), hypersensitive vasculitis, microscopic polyangiitis, Wegener's granulomatosis, and systemic vasculitis (AASV) associated with antineutrophil cytoplasmic antibody (ANCA).

[00230] In some embodiments, the method is a non-Hodgkin's lymphoma (NHL) treatment method selected from relapsed NHL, refractory NHL, and recurrent follicular NHL.

[00231] In some embodiments, the method is a method of treating B-cell lymphoma, wherein said B-cell lymphoma is diffuse large B-cell lymphoma (DLBCL).

[00232] In some embodiments, the method is a method of treating B-cell lymphoma, wherein said B-cell lymphoma is diffuse large B-cell lymphoma of the B-cell-activated type (ABC), or diffuse large B-cell lymphoma of central germinal B-cell (GBC).

[00233] In some embodiments, said disease is osteoarthritis, restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, inflammation, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, or Sjogren's syndrome.

[00234] In some embodiments, said disease is rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus, or inflammation related to any of the above.

[00235] In some embodiments, said lupus is systemic lupus erythematosus or lupus nephritis.

[00236] In some embodiments, said disease is breast cancer, prostate cancer, colon cancer, endometrial cancer, brain cancer, bladder cancer, skin cancer, uterine cancer, ovarian cancer, lung cancer, pancreatic cancer, kidney cancer, gastric cancer or a hematological cancer.

[00237] In some embodiments, said hematological cancer is acute myeloblastic leukemia or chronic myeloid leukemia.

[00238] In some embodiments, said hematologic cancer is lymphoid malignancies of B-cell origin including, indolent/aggressive B-cell non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL).

[00239] In some embodiments, said illness is acute lung injury (ALI) or adult respiratory distress syndrome (ARDS).

[00240] As used herein, the term "contacting" refers to bridging together indicated parts in an in vitro system or an in vivo system. For example, "contacting" PI3K with a compound of the invention includes administering a compound of the present application to an individual or patient, such as a human, having PI3K, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the PI3K.

[00241] As used herein, the term "individual" or "patient", used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably, humans.

[00242] As used herein, the term "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual, or human being by a researcher, veterinarian, physician, or other clinician. In some embodiments, the dosage of the compound, or a pharmaceutically acceptable salt thereof, administered to a patient or individual is about 1 mg to about 2 g, about 1 mg to about 1000 mg, about 1 mg to about 500 mg, about 1 mg to about 100 mg, about 1 mg to 50 mg, or about 50 mg to about 500 mg.

[00243] As used herein, the term "treat" or "treatment" refers to one or more of (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but has not yet experienced or exhibited the pathology or symptomatology of the disease; (2) inhibit the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing the pathology or symptomatology of the disease, condition or disorder (i.e., preventing further development of the pathology and/or symptomatology); and (3) ameliorate the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or exhibiting the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology), such as decreasing the severity of the disease.

COMBINATION THERAPIES

[00244] One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl kinase inhibitors, Flt-3, EGFR, HER2, JAK (for example, JAK1 or JAK2), c-MET, VEGFR, PDGFR, cKit, IGF-1R, RAF, FAK, Akt mTOR, P IM and AKT (e.g. AKT1, AKT2, or AKT3) such as, for example, those described in WO 2006/056399, or other agents such as therapeutic antibodies can be used in combination with the salts or compounds of the present application for the treatment of diseases, disorders or conditions associated with PI3K. The one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.

[00245] In some embodiments, the additional pharmaceutical agent is a JAK1 and/or JAK2 inhibitor. In some embodiments, the present application provides a method of treating a disease described herein (e.g., a B-cell malignancy, such as diffuse B-cell lymphoma) in a patient comprising administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof and a JAK1 and/or JAK2 inhibitor. B-cell malignancies can include those described herein and in Application Serial No. US 61/976,815, filed April 8, 2014.

[00246] In some embodiments, the JAK1 and/or JAK2 inhibitor is a Table 1 compound or a pharmaceutically acceptable salt thereof. The compounds in Table 1 are selective JAK1 inhibitors (selective for JAK2, JAK3 and TYK2). The IC50s obtained by the Assay A method at 1 mM ATP are shown in Table 1. TABLE 1 + means < 10 nM ++ means < 100 nM +++ means < 300 nM aData for enantiomer 1 bData for enantiomer 2

[00247] In some embodiments, the JAK1 and/or JAK2 inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

[00248] In some embodiments, the JAK1 and/or JAK2 inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

[00249] In some embodiments, the JAK1 and/or JAK2 inhibitor is 4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a salt pharmaceutically acceptable thereof.

[00250] In some embodiments, the JAK1 and/or JAK2 inhibitor is selected from (R)-3-[1-(6-chloropyridin-2-yl)pyrrolidin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, (R)-3-(1-[1,3]oxazole [5,4-b]pyridin-2-ylpyrrolidin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, (R)-4-[(4-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl} piperazin-1-yl)carbonyl]-3-fluorobenzonitrile, (R)-4-[(4-{3-cyano-2-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrol-1-yl]propyl}piperazin-1-yl)carbonyl]-3-fluorobenzonitrile, or (R)-4-(4-{3-[(dimethylamino)methyl]-5- fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, (S)-3-[1-(6-chloropyridin-2-yl)pyrrolidin-3-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyra zol-1-yl]propanenitrile, (S)-3-(1-[1,3]oxazolo[5,4-b]pyridin-2-ylpyrrolidin-3-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, (S)-4-[(4-{3-cyano-2-[4-(7H-pyr) rolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperazin-1-yl)carbonyl]-3-fluorobenzonitrile, (S)-4-[(4-{3-cyano-2-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrol-1-yl]propyl}piperazin-1-yl)carbonyl]-3- fluorobenzonitrile, (S)-4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; and pharmaceutically acceptable salts of any of those mentioned above.

[00251] In some embodiments, the JAK1 and/or JAK2 inhibitor is selected from the compounds of U.S. Patent Publication No. 2010/0298334, filed May 21, 2010, Patent Publication No. U.S. 2011/0059951, filed August 31, 2010, Patent Publication No. U.S. 2011/0224190, filed March 9, 2011, Patent Publication No. U.S. 2012/0149681, filed November 18, 2011, Patent Publication No. U.S. 2012/0149682, filed November 18, 2011, Patent Publication No. U.S. 2013/0018034, filed June 19, 2012, Patent Publication No. U.S. 2013/0045963, filed August 17, 2012 and Patent Publication No. U.S. 2014/0005166, filed on May 17, 2013, each of which is hereby incorporated by reference in its entirety.

[00252] Exemplary antibodies for use in combination therapy include, without limitation, trastuzumab (eg, anti-HER2), ranibizumab (eg, anti-VEGF-A), bevacizumab (Avastin™, eg, anti-VEGF), panitumumab (eg, anti-EGFR), cetuximab (eg, anti-EGFR), rituximab (Rituxan™, anti-CD20), and targeted antibodies s for c-MET.

[00253] One or more of the following agents may be used in combination with the salts or compounds of the present application and are presented as a non-limiting list: a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, EGFR antibodies, Gleevec™, intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, Ifosfamide, Melphalan, chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulf an, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Oxaliplatin, Leucovirin, ELOXATIN™, Pentostatin, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Ida rubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesterone acetate, Leuprolide, Flutamide, Toremifene, Goserelin, Cisplatin, Carboplatin, hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Lethrazole, Capecitabine, Reloxafine, Droloxafin, Hexamethyl Melamine, Avastine, Herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozol, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225, Campat, Clofarabine, Cladribine, Afidicolon, Ritux an, sunitinib, dasatinib, tezacitabine, Sml1, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, MDL-101,731, bendamustine (Treanda), ofatumumab, and GS-1101 (also known as CAL-101).

[00254] Exemplary chemotherapeutics include proteasome inhibitors (eg, bortezomib), thalidomide, revlimid, and DNA damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.

[00255] Exemplary steroids include corticosteroids such as dexamethasone or prednisone.

[00256] Exemplary Bcr-Abl inhibitors include the compounds and pharmaceutically acceptable salts thereof, of the genera and species disclosed in US Patent No. 5,521,184, WO 04/005281, and U.S. Application Serial No. 60/578,491.

[00257] Exemplary suitable Flt-3 inhibitors include compounds and their pharmaceutically acceptable salts as disclosed in WO 03/037347, WO 03/099771 and WO 04/046120.

[00258] Exemplary suitable RAF inhibitors include compounds and their pharmaceutically acceptable salts as disclosed in WO 00/09495 and WO 05/028444.

Exemplary suitable FAK inhibitors include compounds and their pharmaceutically acceptable salts as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595 and WO 01/014402.

Exemplary suitable mTOR inhibitors include compounds and their pharmaceutically acceptable salts as disclosed in WO 2011/025889 .

[00261] In some embodiments, the salts and compounds of the invention can be used in combination with one or more other kinase inhibitors including imatinib, particularly to treat patients resistant to imatinib or other kinase inhibitors.

[00262] In some embodiments, the salts and compounds of the invention can be used in combination with a chemotherapeutic in the treatment of cancer, such as multiple myeloma, and can enhance the treatment response in combination with the response to the chemotherapeutic agent alone, without exacerbating its toxic effects. Examples of additional pharmaceutical agents used in the treatment of multiple myeloma, for example, may include, without limitation, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Additionally, additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors. Additive or synergistic effects are desirable results of combining a PI3K inhibitor of the present application with an additional agent. Furthermore, resistance of multiple myeloma cells to agents such as dexamethasone may be reversible upon treatment with the PI3K inhibitor of the present application. The agents can be combined with the present compound in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

[00263] In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with the salts and compounds of the invention when dexamethasone is administered intermittently rather than continuously.

[00264] In some additional embodiments, combinations of the salts and compounds of the invention with other therapeutic agents can be administered to a patient before, during and/or after a bone marrow transplant or stem cell transplant.

PHARMACEUTICAL FORMULATIONS AND DOSAGE FORMS

[00265] When employed as pharmaceuticals, the compounds and salts of the invention can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art and can be administered by a variety of routes, depending on whether local or systemic treatment is desired and the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal application), pulmonary (e.g. by inhalation or insufflation of powders or aerosols, including by nebuliser; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intramuscular, intraperitoneal, subcutaneous, intraarterial or intravenous injection or infusion administration; or intracranial, e.g., intrathecal or intraventricular. Parenteral administration can be in the form of a single bolus dose or can be, for example, by a continuous infusion pump. Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, water, powder or oil bases, thickeners and the like may be necessary or desirable.

[00266] This invention also includes pharmaceutical compositions which contain, as the active ingredient, the compound or salt of the invention (e.g., the hydrochloric acid salt of the compound of Formula I), in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient, or confined within such a vehicle in the form of, for example, a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid or liquid material, which acts as a vehicle, vehicle or medium for the active ingredient. Accordingly, the compositions may be in the form of tablets, pills, powders, lozenges, sachets, capsule-shaped tablets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatine capsules, suppositories, sterile injectable solutions and sterile packaged powders.

[00267] In preparing a formulation, the active compound or salt can be ground to provide the appropriate particle size before combining with the other ingredients. If the active compound or salt is substantially insoluble, it can be ground to a particle size of less than 200 mesh. If the active compound or salt is substantially water soluble, the particle size can be adjusted by grinding to provide a substantially uniform distribution in the formulation, for example about 40 mesh.

[00268] The compounds and salts of the invention can be ground using known grinding procedures such as wet grinding to obtain a particle size suitable for tabletting and other types of formulation. Finely divided (nanoparticulate) preparations of the salts and compounds of the invention can be prepared by processes known in the art, for example, see International Application No. WO 2002/000196.

[00269] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, acacia gum, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide rapid, sustained or delayed release of the active ingredient after administration to the patient employing procedures known in the art.

[00270] The compositions may be formulated in unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the active ingredient. The term "unit dosage forms" refers to physically distinct units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

[00271] In some embodiments, compositions of the invention contain from about 5 to about 50 mg of the active ingredient. One skilled in the art will understand that this incorporates compositions containing about 5 to about 10, about 10 to about 15, about 15 to about 20, about 20 to about 25, about 25 to about 30, about 30 to about 35, about 35 to about 40, about 40 to about 45, or about 45 to about 50 mg of the active ingredient.

[00272] In some embodiments, compositions of the invention contain about 2.5, about 5, about 7.5, about 10, about 12.5, about 15, about 17.5, about 20, about 22.5 or about 25 mg of the active ingredient. In some embodiments, compositions of the invention contain about 5 mg of the active ingredient. In some embodiments, compositions of the invention contain about 10mg of the active ingredient.

[00273] Similar dosages can be used of the compounds and salts described herein in the methods and uses of the invention.

[00274] The active compound or salt can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of compound or salt actually administered will normally be determined by a physician in accordance with the relevant circumstances, including the condition being treated, the chosen route of administration, the actual compound or salt administered, the age, weight and response of the individual patient, the severity of the patient's symptoms and the like.

[00275] To prepare solid compositions such as tablets, the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound or salt of the present application. Referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. The solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present application.

[00276] The tablets or pills of the present application may be coated or otherwise formulated to provide a dosage form providing the advantage of prolonged action. For example, the tablet or pill may comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and allows the internal component to pass intact through the duodenum, or even to be released in a delayed manner. A variety of materials can be used in these enteric layers or coatings, such as materials including numerous polymeric acids and mixtures of polymeric acids with these materials such as shellac, cetyl alcohol and cellulose acetate.

[00277] The liquid forms in which the compounds, salts and pharmaceutical compositions of the present application can be incorporated for oral administration or by injection include, aqueous solutions, suitably flavored syrups, aqueous or oily suspensions and emulsions flavored with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

[00278] Compositions for inhalation and insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the compositions are administered via the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by the use of inert gases. Nebulized solutions can be breathed directly from the nebulizer device or the nebulizer device can be attached to a face mask chamber or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices that deliver the formulation in an appropriate manner.

[00279] Topical formulations may contain one or more conventional carriers. In some embodiments, ointments may contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white petroleum jelly and the like. Cream carrier compositions can be water based in combination with glycerol and one or more other components, for example glycerin monostearate, PEG-glycerin monostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, for example, glycerol, hydroxyethyl cellulose and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5% by weight of the compound or salt of the invention. Topical formulations may suitably be packaged in tubes of eg 100g which are optionally associated with instructions for treating the selected indication eg psoriasis or other skin condition.

[00280] The amount of compound, salt or composition administered to a patient will vary depending on what is being administered, the purpose of administration such as prophylaxis or therapy, the condition of the patient, the manner of administration and the like. In therapeutic applications, the compositions can be administered to a patient already suffering from a disease in an amount sufficient to at least partially cure or end the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as the judgment of the attending physician depending on such factors as the severity of the disease, the age, weight and general condition of the patient and the like.

[00281] Compositions administered to a patient may be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques or can be filtered to sterilization. Aqueous solutions may be packaged for use as is or lyophilized, the lyophilized preparation being combined with a sterile aqueous vehicle prior to administration. The pH of compound preparations will typically be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It will be understood that the use of certain excipients, carriers or stabilizers above will result in the formation of pharmaceutical salts.

[00282] The therapeutic dosage of a compound or salt of the present application may vary according to, for example, the particular use for which the treatment is given, the manner of administration of the compound or salt, the health and condition of the patient and the judgment of the prescribing physician. The proportion or concentration of a compound or salt of the invention in a pharmaceutical composition can vary depending on a number of factors including dosage, chemical characteristics (e.g., hydrophobicity) and the route of administration. For example, the compounds and salts of the invention can be supplied in aqueous physiological buffer containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 dg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the general health condition of the particular patient, the relative effectiveness of the selected compound, the formulation of the excipient and its route of administration. Effective dosages can be extrapolated from these dose-response curves derived from animal model or in vitro test systems.

[00283] Compositions of the invention may further include one or more additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are provided herein.

KITS

[00284] The present application also includes pharmaceutical kits useful, for example, in the treatment or prevention of diseases or disorders associated with PI3K, such as cancer, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention. Such kits may further include, if desired, one or more of a number of conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating amounts of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.

[00285] The invention will be described in more detail by way of specific examples. The following examples are offered for purposes of illustration and are not intended to limit the invention in any way. Those skilled in the art will readily recognize a variety of non-critical parameters that can be changed or modified to yield essentially the same results. The hydrochloric acid salt of the compound of Formula I and the compound of Formula I have been found to be PI3K inhibitors according to at least one assay described herein.

EXAMPLES

[00286] The invention will be described in more detail by way of specific examples. The following examples are offered for purposes of illustration and are not intended to limit the invention in any way. Exemplary compounds, or salts thereof, containing one or more chiral centers were obtained in racemate form or as isomeric mixtures, unless otherwise specified.

GENERAL METHODS

[00287] Preparatory LC-MS purifications of some of the prepared compounds were performed on Waters directed mass fractionation systems. The configuration of basic equipment, protocols and control software for the operation of these systems have been described in more detail in the literature. See, for example, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874 to 883 (2004). The separated compounds were typically subjected to liquid chromatography/analytical mass spectrometry (LCMS) for purity analysis under the following conditions: Instrument; Agilent 1100 series, LC/MSD, Column: Waters SunfireTM Cie 5 µm, 2.1 x 50 mm, Buffers: mobile phase: A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% B in 3 minutes with a flow rate of 2.0 ml/minute.

[00288] Some of the prepared compounds were also separated on a preparatory scale by reverse phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical reversed phase preparative high performance liquid chromatography (RP-HPLC) column conditions are as follows:

[00289] pH = 2 purifications: Waters SunfireTM C18 5 μm , 19 x 100 mm column, elution with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; flow rate was 30 ml/minute, the separation gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874 to 883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 ml/minute.

[00290] pH = 10 Purifications: Waters XBridge C18 5 µm, 19 x 100 mm column, elution with mobile phase A: 0.15% NH4OH in water and mobile phase B: acetonitrile; the flow rate was 30 ml/minute, the separation gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874 to 883 (2004)]. Typically, the flow rate used with a 30 x 100 mm column was 60 ml/minute.

[00291] Some of the compounds prepared were also analyzed using Differential Scanning Calorimetry (DSC). Typical DSC instrument conditions were as follows:

[00292] TA Instrument Differential Scanning Calorimetry, Model Q200 with autosampler: 30 to 350°C at 10°C/min; T-zero aluminum sample pot and lid; Nitrogen gas flow at 50 ml/min.

[00293] Mettler Toledo Differential Scanning Calorimetry (DSC) Instrument 822: 40 to 340°C at a heating rate of 10°C/min.

[00294] Some of the prepared compounds were also analyzed using Thermogravimetric Analysis (TGA). Typical TGA instrument conditions were as follows:

[00295] TA Instrument Thermogravimetric Analyzer, Model Pyris: Temperature ramp from 25°C to 300°C at 10°C/min; nitrogen gas purge flow at 60 ml/min; TGA ceramic crucible sample holder.

[00296] TA Instrument Q500: Temperature ramp from 20 °C to 300 °C at 10 °C/min.

[00297] Some of the prepared compounds were also analyzed by X-Ray Powder Diffraction (XRPD). Typical XRPD instrument conditions were as follows:

[00298] Bruker D2 PHASER X-ray Powder Diffractometer instrument: X-ray radiation wavelength: X-ray powders 1.05406 Â CuKAI;: 30 KV, 10 mA; sample powders: dispersed in a zero background sample holder; general measurement conditions: start angle - 5 degrees, stop angle - 60 degrees, Sampling - 0.015 degrees, Sweep speed - 2 degrees/min.

[00299] Rigaku Miniflex Powder Diffractometer: Cu at 1.054056 Â with Kβ filter; general measurement conditions: start angle - 3 degrees, stop angle - 45 degrees, Sampling - 0.02 degrees, Sweep speed - 2 degrees/min. EXAMPLE 1. SYNTHESIS OF (R)-4-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((R)-1-HYDROXYETHYL)PHENYL)PYRROLIDIN-2-ONE STEP 1. 1-(5-CHLORO-4-FLUORO-2-HYDROXYPHENYL)ETHANONE (II)

[00300] 4-Chloro-3-fluorophenol (i, 166 g, 1.11 mol) and acetyl chloride (107 ml, 1.50 mol) were charged into a 5 liter flask at room temperature. The reaction mixture was stirred and turned into a clear solution while recording that the batch temperature dropped to 6°C. The reaction mixture was then heated at 60°C for 2 hours. The reaction mixture was charged with nitrobenzene (187.5 ml, 1.82 mol) and subsequently cooled to room temperature. Aluminum trichloride (160 g, 1.2 mmol) was then added to the mixture in three portions (50 g, 50 g, and 60 g at 5 min intervals). The batch temperature increased to 78°C at the end of the addition. The reaction mixture was then heated at 100 to 120°C for 3 hours, at which time HPLC analysis showed that the reaction was complete. The reaction mixture was then cooled to 0°C and charged with hexanes (0.45 L), ethyl acetate (0.55 L) and then charged slowly with 1.0 N aqueous hydrochloric acid (1.0 L) at room temperature. The addition of aqueous hydrochloric acid was exothermic and the batch temperature increased from 26°C to 60°C. The resulting mixture was stirred at room temperature for 20 minutes. The layers were separated and the organic layer was washed sequentially with 1.0N aqueous hydrochloric acid (2 x 600 ml) and water (400 ml). The organic layer was then extracted with 1.0 N aqueous sodium hydroxide solution (2 x 1.4 L). The combined basic solutions were acidified to pH 2 by the addition of 12% aqueous hydrochloric acid until no further precipitate separated. The resulting solid was collected by filtration, washed with water and dried on the filter funnel under suction to yield compound ii as a yellow solid (187.4g, 89.5%). 1H NMR (400 MHz, CDCl3) δ 12.44 (d, J = 1.4 Hz, 1H), 7.78 (d, J = 8.1 Hz, 1H), 6.77 (d, J = 10.2 Hz, 1H), 2.61 (s, 3H). STEP 2. 1-(5-CHLORO-4-FLUORO-2-HYDROXY-3-IODOPHENYL)ETHANONE (III)

[00301] 1-(5-Chloro-4-fluoro-2-hydroxyphenyl)ethanone (ii, 100.0 g, 530.3 mmol) was dissolved in acetic acid (302 mL) and N-iodosuccinimide (179.2 g, 796.5 mmol) was added to the solution. The reaction mixture was stirred from about 61°C to about 71°C for 2 hours, at which time HPLC analysis indicated that the reaction was complete. The reaction mixture was then cooled to room temperature, water (613 ml) was added and the resulting aqueous slurry was stirred at room temperature for 30 minutes. The product was collected by filtration and rinsed with water to give brown solids. The wet product was dissolved in acetic acid (400 ml) at 60°C. Water (800 ml) was added (over 15 minutes) to the solution to precipitate pure product. The product was collected by filtration and washed with water (100 ml). The product was dried on the filter funnel under suction for 18 hours to yield compound iii as a brown solid (164.8g, 95.0% yield). 1H NMR (300 MHz, DMSO-d6) δ13.34 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 2.68 (s, 3H). STEP 3. 1-(5-CHLORO-2-ETHOXY-4-FLUORO-3-IODOPHENYL)ETHANONE (IV)

[00302] In a 5-liter three-neck round bottom flask equipped with a condenser and a thermometer, 1-(5-chloro-4-fluoro-2-hydroxy-3-iodophenyl)ethanone (iii, 280 g, 840 mmol) was dissolved in N,N-dimethylformamide (600 mL). During dissolution, the internal temperature dropped from 19.3°C to 17.0°C. Iodoethane (81.2 ml, 1020 mmol) was added to the resulting mixture. Potassium carbonate (234 g, 1690 mmol) was then added over 2 minutes to the reaction mixture and no change in batch temperature was observed. The reaction mixture was heated to 60°C for 3 hours, at which time HPLC analysis indicated that the reaction was complete. The reaction mixture was allowed to cool to room temperature and the product was collected by filtration. The solids were dissolved in a mixture of DCM (1.0 L), hexane (500 ml) and water (2.1 L). The biphasic system was stirred at 20°C for 20 minutes. The layers were separated and the aqueous layer was extracted with DCM (1.0 L). The combined organic layer was washed with water (2 x 250 ml) and brine (60 ml). The organic phase was separated, dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to dryness to yield compound iv as a yellow solid (292 g, 94% yield). 1H NMR (400 MHz, DMSO-d6) δ7.69 (d, J = 8.4 Hz, 1H), 3.95 (q, J = 7.0 Hz, 2H), 2.62 (s, 3H), 1.49 (t, J = 7.0 Hz, 3H). LCMS for C10H10ClFIO2 (M + H)+: m/z = 342.9. STEP 4. 2-(5-CHLORO-2-ETHOXY-4-FLUORO-3-IODOPHENYL)-2- METHYL-1,3-DIOXOLANE (V)

[00303] A solution of 1- (5-chloro-2-etoxi-4-fluoro-3- iodophenyl) ethanone (IV, 250.0 g, 693.4 mmols) and 1.2-dietary (58.0 mL, 1040 mmols) in toluene (1.5 L) was treated with monohydrated p-toluenosulphonic acid (10.6 g, 55.5 mmols). The reaction flask was fitted with a Dean-Stark trap and the mixture was heated to reflux for 7 hours. LCMS analysis indicated that the reaction mixture contained 8.3% starting material and 91.7% product. The reaction mixture was cooled to 106°C and an additional amount of 1,2-ethanediol (11.6 ml, 208 mmol) was introduced via syringe. The reaction mixture was then heated to reflux for an additional 8 hours. LCMS analysis indicated that the reaction mixture contained 3.6% starting material and 96.4% product. The reaction mixture was cooled to 106 °C and additional 1,2-ethanediol (7.73 mL, 139 mmol) was introduced via syringe. The reaction mixture was heated under reflux for an additional 15.5 hours. LCMS analysis indicated that the reaction mixture contained 2.2% starting material and 97.8% product.

[00304] The reaction mixture was then cooled to 0 °C and water (200 ml) and saturated aqueous NaHCO 3 (300 ml) were added to adjust the mixture to a pH of 9. DCM (200 ml) was added and the batch stirred for 10 minutes. The layers were separated and the aqueous layer was extracted with toluene (300ml). The combined organic layer was washed sequentially with a mixture of water (200 ml) and saturated aqueous NaHCO3 (200 ml), water (300 ml), brine (300 ml), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to dryness to give crude compound v as a light brown solid (268 g, 100% yield). 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 8.6 Hz, 1H), 4.26 and 3.96 (m, 4H), 3.92 and 3.72 (m, 2H), 1.74 (s, 3H), 1.50 (t, J = 7.0 Hz, 3H). LCMS for C12H14ClFIO3 (M + H)+: m/z = 387.0. STEP 5. 3-CHLORO-6-ETHOXY-2-FLUORO-5-(2-METHYL-1,3-DIOXOLAN-2-IL)BENZALDEHYDE (VI)

[00305] To a stirred solution of 2-(5-chloro-2-ethoxy-4-fluoro-3-iodophenyl)-2-methyl-1,3-dioxolane (v, 135.0 g, 349.2 mmol) (86.8% purity by HPLC with 5.5% of the ketone) in anhydrous tetrahydrofuran (300 ml) at about 0°C to about 3°C was 1.3 M isopropylmagnesium lithium chloride complex in THF (322.3 ml, 419.0 mmol) is slowly added over 1 hour. The reaction mixture was stirred at about 0°C to about 5°C for 30 minutes, at which time LCMS analysis indicated that the iodine-magnesium exchange reaction was complete. N-formylmorpholine (71.1 ml, 700 mmol) was then added to the reaction mixture over 1 hour at about 0°C to about 8°C. The reaction mixture was stirred at about 0°C to about 8°C for an additional 1 hour, at which time analysis by LCMS and HPLC showed that the starting material was consumed and a significant amount of deiodination by-product, 2-(5-chloro-2-ethoxy-4-fluorophenyl)-2-methyl-1,3-dioxolane was observed. The reaction was quenched with an aqueous solution of citric acid (120.8 g, 628.6 mmol) in water (1.20 L) at 0 °C. The quenched reaction mixture was then extracted with EtOAc (2 x 600 ml). The phases were promptly separated. The combined organic layer was washed sequentially with water (300 ml) and brine (500 ml), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel with 0 to 10% EtOAc/hexane to yield the crude product compound vi as a pale yellow solid, which was a mixture of the desired product, 3-chloro-6-ethoxy-2-fluoro-5-(2-methyl-1,3-dioxolan-2-yl)benzaldehyde (vi, 80 g, 80%) containing 36 mole % deiodination by-product , 2-(5-chloro-2-ethoxy-4-fluorophenyl)-2-methyl-1,3-dioxolane as indicated by NMR analysis. The crude product compound vi was further purified by formation of the corresponding sodium bisulfite adduct.

[00306] Sodium bisulfite (36.91 g, 354.7 mmol) was dissolved in water (74.3 ml, 4121 mmol). To a stirred solution of crude 3-chloro-6-ethoxy-2-fluoro-5-(2-methyl-1,3-dioxolan-2-yl)benzaldehyde (vi, 80.00 g, 177.3 mmol) in ethyl acetate (256.0 mL), freshly prepared sodium bisulfite solution was added in one portion. The solution was stirred for about 10 minutes and precipitates were observed. The aqueous slurry was then stirred for an additional 1 hour. The aldehyde-bisulphite adduct was collected by filtration, washed with EtOAc and dried under vacuum and nitrogen atmosphere for 20 hours to yield a white solid (58.2 g, 83.6% yield). To the aldehyde bisulfite adduct (58.2 g, 148 mmol) mixed in 1.0 M aqueous sodium hydroxide (296 ml, 296 mmol) was added methyl t-butyl ether (600 ml) (MTBE). The reaction mixture was stirred at room temperature for 6 minutes to yield a clear biphasic mixture and stirring was continued for a further 5 minutes. The organic phase was collected and the aqueous layer was extracted with MTBE (2 x 300 ml). The combined organic layers were washed with brine (300 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo to yield pure compound vi as a white crystalline solid (31.4 g, 73.4% yield). 1H NMR (400 MHz, CDCl3) δ 10.27 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 4.10 and 3.96 (m, 4H), 3.87 and 3.76 (m, 2H), 1.72 (s, 3H), 1.44 (t, J = 7.0 Hz, 3H). LCMS for C13H15ClFO4 (M + H)+: m/z = 289.0. STEP 6. (E)-2-(5-CHLORO-2-ETHOXY-4-FLUORO-3-(2-NITROVINYL)PHENYL)-2-METHYL-1,3-DIOXOLANE (VII)

[00307] Into a 5-liter, 4-neck round bottom flask equipped with an overhead stirrer, septa, thermocouple, nitrogen inlet and condenser was charged 3-chloro-6-ethoxy-2-fluoro-5-(2-methyl-1,3-dioxolan-2-yl)benzaldehyde (vi, 566.2 g, 1961 mmol), nitromethane (1060 ml, 19600 mmol) and glacial acetic acid (1120 ml). Subsequently, the reaction mixture was charged with benzylamine (53.6 ml, 490 mmol) and the resulting mixture was heated to 60 °C and the reaction was monitored by LCMS for 5.5 hours. An initial baseline analysis was taken at t = 0. The reaction was checked after 2 hours and 5 hours. After 2 hours, there was about 20% aldehyde of unreacted starting material. After 5 hours, the reaction profile was as follows: starting material compound vi (< 2%), intermediate imine (< 4%), product compound vii (> 93%) and benzylamine adduct Michael (not detected). At the reaction time of 5.5 hours, the reaction was considered complete. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (3.0 L). The mix was split in half for work due to the large volume involved.

[00308] Each half was treated according to the following procedure: The reaction mixture was first washed with 1.5 M NaCl in water (2 x 1500 ml; after each wash, the aqueous volume output increased compared to the input, suggesting that acetic acid and/or nitromethane were being removed). The mixture was then cooled to about 15 °C and washed with 4 M aqueous NaOH solution (4 x 300 ml) until the aqueous extract reached a pH of 8 to 9. During the initial washes, the aqueous layer remained acidic, however, as the aqueous layer became slightly basic during subsequent washes, the mixture was heated and the extract was dark. The layers have been separated. The organic layer after pH adjustment was then washed with 1.5 M sodium chloride in water (1000 ml) and water (500 ml). Emulsion and slow partitioning were observed during these final washes. The organic phase was dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The resulting amber syrup was placed under high vacuum overnight. The syrup solidified and 740 g of crude product were obtained.

[00309] Heptane (1.3 l) was added to the crude product, forming an aqueous slurry, which was heated in a 60°C water bath until all solids were dissolved. The resulting solution was filtered into a clear 3-liter 4-neck round bottom flask equipped with an overhead stirrer and nitrogen inlet. The filter was rinsed with heptane (40 ml). The filtered solution was cooled to room temperature and stirred for 5 hours. Solid precipitates were observed and the aqueous slurry was cooled to 0°C in an ice bath for 1 hour. The product was collected by filtration and the resulting wet cake was washed with 500 ml of ice-cold heptane. The product was partially dried on the filter under vacuum suction and further dried under high vacuum overnight. The filtrate and washing solution were concentrated under reduced pressure and the resulting residue was kept for column purification.

[00310] Heptane crystallization solids were dissolved in a small volume of DCM and 20% EtOAc/hexane and loaded onto a column containing about 1 kg of silica gel. The column was eluted with 20% EtOAc/hexane. The desired fractions were combined and concentrated under reduced pressure to yield a yellow solid. The solid was dried under high vacuum overnight to yield 497 g of product compound vii as a pale yellow crystalline solid.

[00311] The concentrated filtrate and the heptane crystallization wash were loaded onto the same column as above using 20% EtOAc/hexane. The column was eluted using the same solvent system as above to remove baseline impurities and residual acetic acid. The desired fractions were combined and concentrated under reduced pressure to yield a reddish amber oil. The oil was placed under high vacuum and about 220 g of crude product were obtained. This crude product was dissolved in heptane (500 ml) and considered with a small amount of the first crop solid product. The aqueous slurry was stirred at room temperature for 16 hours and then cooled in an ice bath for 3 hours. The second crop product was collected by filtration. The product was dried under high vacuum and 110 g of product was obtained as a yellow solid. The total amount of product compound vii obtained was 607 g (93.3% yield). 1h NMN (400 MHz, DMSO-D6) Δ 7.94 (S, 2h), 7.68 (D, J = 8.9 Hz, 1h), 4.07 and 3.95 (m, 4h), 3.82 and 3.73 (m, 2h), 1.65 (s, 3h), 1.39 (t, j = 7.0 Hz, 3h). LCMS for C14H16ClFNO5 (M + H)+: m/z = 332.0. STEP 7. (R)-DIMETHYL-2-(1-(3-CHLORO-6-ETHOXY-2-FLUORO-5-(2-METHYL-1,3-DIOXOLAN-2-YL)PHENYL)-2-NITROETHYL)MALONATE (VIII)

[00312] In a 2 liter round bottom flask with a magnetic stirring bar and nitrogen inlet containing (E)-2-(5-chloro-2-ethoxy-4-fluoro-3-(2-nitrovinyl)phenyl)-2-methyl-1,3-dioxolane (vii, 352.8 g, 1064 mmol) were added anhydrous tetrahydrofuran (1.06 l) and dimethyl malonate a (146 ml, 1280 mmol). (1S,2S)-N,N'-dibenzylcyclohexane-1,2-dibromoniquel-diamine (Evans Catalyst, 21.4 g, 26.6 mmol) was charged into the reaction mixture. The reaction mixture was brown in color and a homogeneous solution was observed. The reaction mixture was stirred at room temperature for 18.5 hours. The reaction was analyzed after 18.5 hours by HPLC. Unreacted starting material, compound vii, was present at 2%. The reaction mixture was concentrated under reduced pressure to remove THF and the resulting residue was purified by flash chromatography (DCM/hexanes used for loading, 1422 g of silica gel was used for this column and the column was eluted with 10% to 20% EtOAc/hexane; column fractions were monitored by TLC using 30% EtOAc/hexane as eluent and visualized by UV). The desired fractions were combined and concentrated under reduced pressure. The residue was dried under high vacuum. Over time, the syrup solidified to light yellow solids (503.3g) and a sample was taken for chiral HPLC analysis. The chiral purity was 95.7% of the desired (R)-enantiomer and 4.3% of the undesired (S)-enantiomer. Ethanol (1.0 L) was added to the solids and the mixture was heated in a 60°C water bath until the solids dissolved. The solution was filtered into a clear 3 liter 4 neck round bottom flask through Whatman #1 filter paper. The filtered solution was cooled to room temperature while stirring. Crystallization was observed after 30 minutes of stirring and the aqueous slurry was stirred at room temperature for 16 hours. The aqueous slurry was cooled in an ice bath for 1 hour. The product was collected by filtration and the resulting filter cake was washed with ice cold ethanol (500 ml) and partially dried on the filter. The solids were dried under high vacuum to yield the desired product viii (377.5g) as white crystalline solids. Chiral purity was determined by chiral HPLC as 100% of the desired (R)-enantiomer and 0% of the undesired (S)-enantiomer.

[00313] The filtrate and wash were combined and concentrated under reduced pressure to an oil (118.9 g). The oil was dissolved in ethanol (475.0 ml) (4 ml/g) and considered with the first crop crystals. The resulting aqueous slurry was stirred for 16 hours at room temperature and then cooled in an ice bath for 5.5 hours. The second crop product was isolated by filtration and partially dried on the filter. It was dried under high vacuum to yield the second crop product (31.0 g). Chiral purity was determined by chiral HPLC as 98.3% of the desired (R)-enantiomer and 1.7% of the undesired (S)-enantiomer. The combined yield of the first and second crops of product was 408.5 g at 82.8% yield. 1H NMR (500 MHz, DMSO and d6) δ 7.51 (d, J = 9.0 Hz, 1H), 5.20 and 4.81 (m, 2H), 4.62 (m, 1H), 4.14 and 4.03 (m, 2H), 4.03 and 3.97 (m, 2H), 3.95 and 3.88 (m, 1H), 3.84 and 3.72 (m, 2H), 3.70 (s, 3H), 3.38 (s, 3H), 1.61 (s, 3H), 1.39 (t, J = 6.9 Hz, 3H). LCMS for C19H24ClFO9 (M + H)+: m/z = 463.9. STEP 8. (R)-DIMETHYL 2-(1-(3-ACETYL-5-CHLORO-2-ETHOXY-6-FLUOROPHENYL)-2-NITROETHYL)MALONATE (IX)

[00314] To a stirred solution of (R)-dimethyl-2-(1-(3-chloro-6-ethoxy-2-fluoro-5-(2-methyl-1,3-dioxolan-2-yl)phenyl)-2-nitroethyl)malonate (viii, 244.0 g, 526.0 mmol) in acetone (1.2 l) in a 5 liter three-necked round bottom flask equipped with a mechanical stirrer, iodine (13.4 g, 52.6 mmol) was added at room temperature. The resulting brown solution was heated at 50°C in a water bath for 30 minutes, at which time LCMS analysis showed that the reaction was complete. The reaction mixture was cooled to room temperature and then quenched with a solution of sodium thiosulphate (17.0 g, 108 mmol) in water (160 mL) to yield a clear pale yellow solution. At this time, an additional amount of water (1.2 L) was charged into the quenched solution and the resulting white aqueous slurry was stirred at room temperature for 1 hour. The solid was then collected by filtration and redissolved in acetone (1.4 L) at 40°C. The solution was cooled to room temperature and then additional water (1.4 L) was added. The resulting white aqueous slurry was stirred at room temperature for 1 hour. The solid was collected by filtration and washed with water (3 x 100 ml). The solid product was dried on a filter funnel under suction with a nitrogen flow for 46 hours to yield compound ix as a white solid (212 g, 96% yield). 1H NMR (300 MHz, CDCl3) δ 7.54 (d, J = 8.6 Hz, 1H), 5.09 and 4.67 (m, 3H), 4.10 and 3.83 (m, 3H), 3.90 (s, 3H), 3.57 (s, 3H), 2.57 (s, 3H), 1.46 (t, J = 7.0Hz, 3H). LCMS for C17H20ClFNO8 (M + H)+: m/z = 420.1. STEP 9. DIMETHYL 2-((R)-1-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((R)-1-HYDROXYETHYL)PHENYL)-2-NITROETHYL)MALONATE (X)

[00315] To a stirred solution of (3aS)-1-methyl-3,3-diphenyltetrahydro-3H-pyrrolo[1,2-c][1,3,2]oxazaborol, ((S)-MeCBS, 16.39 g, 59.12 mmol, 0.1 eq.) in anhydrous THF (100 ml) in a 5 liter round bottom flask at room temperature was added a solution of 1.0 M borane-THF complex in THF (591 ml, 591 mmol, 1 eq.) followed by boron trifluoride etherate (3.75 ml, 29.6 mmol, 0.05 eq). The resulting solution was stirred at room temperature for 30 minutes. A solution of dimethyl [(1R)-1-(3-acetyl-5-chloro-2-ethoxy-6-fluorophenyl)-2-nitroethyl]malonate (ix, 253.0 g, 591.2 mmol) in anhydrous THF (1.7 L) was then added dropwise through an addition funnel over 60 minutes. The vial containing the ix ketone was rinsed with anhydrous THF (135 ml) and the solution was added dropwise through the addition funnel to the reaction mixture. The resulting solution was stirred at room temperature for an additional 10 minutes, at which time LCMS analysis showed complete conversion of the ketone to the alcohol. The reaction was quenched by dropwise addition of methanol (71.8 ml, 1770 mmol) at 0°C. The quenched reaction mixture was stirred at room temperature for 15 minutes before it was concentrated in vacuo to yield the crude product. The crude products from this batch and a similar batch (using 200 g of starting material) were combined and purified by silica gel column chromatography using 0 to 5% MeOH/DCM as eluant to yield compound x as a white solid (437 g, 97.9% yield). 1H NMR (300 MHz, CDCl3) δ 7.50 (d, J = 8.8 Hz, 1H), 5.13 (q, J = 6.3 Hz, 1H), 5.01 and 4.65 (m, 3H), 4.14 and 3.89 (m, 3H), 3.79 (s, 3H), 3.57 (s, 3H), 1 .57 and 1.42 (m, 6H). LCMS for C17H21ClFNNaO8 (M + Na)+: m/z = 444.0. STEP 10. 4-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((R)-1-HYDROXYETHYL)PHENYL)-2-OXOPYRROLIDINE-3-(4R)-METHYL CARBOXYLATE (XI)

[00316] A 3-neck Morton round bottom flask containing dimethyl ((1R)-1-{3-chloro-6-ethoxy-2-fluoro-5-[(1R)-1-hydroxyethyl]phenyl}-2-nitroethyl)malonate (x, 100.0 g, 237.1 mmol) in tetrahydrofuran (800.0 ml) and Raney nickel (120 g after removal of water by pipette) was equipped with a condenser, a mechanical stirrer (glass stirring bar and Teflon holder) and two flasks of hydrogen gas (after vacuum purging). The flask was placed in an oil bath at 65°C. The batch was shaken vigorously for 16 hours and the flasks were periodically removed and recharged with hydrogen. A sample was taken and analyzed by HPLC. The product, compound xi, was present at 83%. There was 7.8% uncyclized amine and 5.5% hydroxylamine by-product in the reaction mixture. The catalyst was filtered (care should be taken not to allow the Raney Nickel to dry out on exposure to air). The filtrate was evaporated to dryness to yield 91g of crude product as a white foam. The crude product (91 g, 82.6% purity by area) was combined with another similar batch of crude product (93 g, 72.8% purity) for purification. The combined crude product (184 g) was purified by column chromatography on silica gel (EtOAc/hexane as eluent) to yield compound xi (101.1 g, 93% HPLC purity, 59.3% crude yield). The crude material was used for the next reaction without further purification. LCMS for C16H20ClFNO5 (M + H)+: m/z = 360.0. STEP 11. (4R)-4-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((R)-1-HYDROXYETHYL)PHENYL)-2-OXOPYRROLIDINE-3-CARBOXYL ACID (XII)

[00317] A solution of (4R)-methyl 4-(3-chloro-6-ethoxy-2-fluoro-5-((R)-1-hydroxyethyl)phenyl)-2-oxopyrrolidine-3-carboxylate (4R)-methyl (xi, 268 g, 581 mmol) in tetrahydrofuran (21 50 ml, 26500 mmol). To the solution, 1.0 M sodium hydroxide in water (1420 mL, 1420 mmol) was charged. The resulting cloudy solution became clear within 1 minute. The reaction mixture was stirred overnight at room temperature. The reaction was analyzed by LCMS after 15 hours and appeared to be complete as starting material was not observed. The reaction mixture was cooled in an ice bath to an internal temperature of 9.5 °C and the mixture was acidified to pH 1 to 2 by the addition of 6.0 M aqueous hydrochloric acid (237.0 mL, 1422 mmol) via a dropping funnel over 30 minutes. The reaction mixture was divided in half and each half was extracted with ethyl acetate (2 x 1 L). The combined aqueous layers were further extracted with ethyl acetate (500ml). The two organic layers were washed with brine (20 wt% NaCl/water, 2 x 1000 ml), dried over anhydrous MgSO 4 , filtered and concentrated to yield the crude intermediate acid xii as a yellowish foam which was used directly in the next reaction. 1H NMR (400 MHz, DMSO and d6) δ12.68 (br s, 1H), 8.26 (s, 1H), 7.52 (d, J = 8.0 Hz, 1H), 5.27 (br s, 1H), 4.90 (q, J = 6.3 Hz, 1H), 4.28 (q, J = 8.8 Hz, 1H ), 3.92 and 3.81 (m, 1H), 3.76 and 3.65 (m, 1H), 3.57 (t, J = 9.6 Hz, 1H), 3.46 (d, J = 9.4 Hz, 1H), 3.23 (q, J = 9.5 Hz, 1H), 1.33 (t, J = 6.9 Hz, 3H), 1 .28 (d, J = 6.4 Hz, 3H). LCMS for C15H17ClFNNaO5 (M + Na)+: m/z = 368.0. STEP 12. (R)-4-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((R)-1-HYDROXYETHYL)PHENYL)PYRROLIDIN-2-ONE (XIII)

[00318] The crude compound xii was dissolved in 1,4-dioxane (976 ml) and toluene (976 ml) and the resulting yellow solution was heated to 100°C. The color of the solution turned brown as the reaction progressed. Samples were taken at time points 1 hour, 2 hours and 2.5 hours. At 2.5 hours, HPLC analysis showed that the acid, compound 12, was at 0.38% and the desired product, compound xiii, at 78.8%. The reaction mixture was cooled to room temperature and filtered into a clear 3 liter round bottom flask. The solution was then concentrated under reduced pressure and the resulting residue placed under high vacuum to yield a brown foam (254g).

[00319] Acetonitrile (350 ml) was charged into the brown syrup and heated in a water bath at 65°C until dissolution was observed. The solution was cooled to room temperature and stirred for 16 hours. Solids were separated from the solution. The resulting aqueous slurry was cooled in an ice bath for 1 hour. The product was collected by filtration and the filter cake was rinsed with 400 ml ice-cold acetonitrile. The solids appeared to be hygroscopic. The solid was dissolved in DCM (2.0 L) and concentrated to a syrup which was placed under high vacuum to yield compound xiii as a white foam (106.4 g).

[00320] The filtrate was concentrated to a dark syrup (about 120 g) which was purified by flash chromatography (4 x 330 silica gel columns, loaded with DCM, eluted with 50% to 100% EtOAc/hexane and monitored by TLC using 100% EtOAc as eluent). Fractions from the chromatography were concentrated under reduced pressure and placed under high vacuum to yield a light brown foam (54.4 g). The foam was charged with MTBE (400 ml) and MeOH (10 ml) and heated in a 56°C water bath for 15 minutes and some solids remained. The aqueous slurry was cooled to room temperature with stirring. The aqueous slurry was filtered to remove insoluble substances. The filtrate was concentrated to a syrup and placed under high vacuum to yield a foam. The foam was charged with acetonitrile (72 ml, 1.5 ml/g) and heated in a 60°C water bath until the solution became homogeneous. The solution was cooled to room temperature with stirring and solids precipitated out of solution and became very thick. Additional acetonitrile (24 ml) was added to adjust the dilution to 2 ml/g. The aqueous slurry was stirred at room temperature for 16 hours and then cooled in an ice bath for 1 hour. The product was collected by filtration and rinsed with acetonitrile. Compound xiii (25 g) was obtained as a second crop. A total of 131.4 g of compound xiii was obtained in 74.9% yield of compound xi. 1H NMR (400 MHz, DMSO and d6) δ 7.83 (s, 1H), 7.47 (d, J = 8.7 Hz, 1H), 5.24 (d, J = 4.5 Hz, 1H), 4.96 and 4.85 (m, 1H), 4.08 and 3.92 (m, 1H), 3.80 (qt, J = 6.9, 3.5 Hz, 2H), 3.61 and 3.51 (m, 1H), 3.25 (t, J = 9.1 Hz, 1H), 2.61 and 2.50 (m, 1H), 2.35 and 2.26 (m, 1H), 1.33 (t, J = 7.0 Hz, 3H), 1.27 (d, J = 6 .4Hz, 3H). LCMS for C14H18ClFNO3 (M + H)+: m/z = 302.0. EXAMPLE 2. ALTERNATIVE SYNTHESIS OF (R)-4-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((R)-1-HYDROXYETHYL)PHENYL)PYRROLIDIN-2-ONE STEP 1. 1-(5-CHLORO-2-ETHOXY-4-FLUOROPHENYL)ETHANONE (IV-A)

[00321] 1-(5-Chloro-4-fluoro-2-hydroxyphenyl)ethanone (Compound ii from Example 1, Step 1, 1350 g, 7160 mmol), N,N-dimethylformamide (3.32 L), iodoethane (1340 g, 8590 mmol) and potassium carbonate (1980 g, 14300 mmol) were mixed and stirred s at room temperature for 45 minutes. The batch temperature was up to 55°C from 22°C. The reaction mixture was heated to 60°C for 1 hour (batch temperature reached 67°C within 30 minutes and then dropped to 60°C). HPLC analysis indicated that all starting material was consumed. Water (10 L) was added in one portion (stirring will stop if water is added in portions). The resulting aqueous slurry was stirred at room temperature for 30 minutes. The product was collected by filtration and rinsed with water (3 L). The product dried on the filter under vacuum for 5 days to yield compound iv-a as a brown solid (1418g). 1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 8.9 Hz, 1H), 7.30 (d, J = 11.6 Hz, 1H), 4.15 (q, J = 7.0 Hz, 2H), 2.51 (s, 3H), 1.37 (t, J = 7.0 Hz, 3H). STEP 2. 2-(5-CHLORO-2-ETHOXY-4-FLUOROPHENYL)-2-METHYL-1,3-DIOXOLANE (VA)

[00322] A solution of 1-(5-chloro-2-ethoxy-4-fluorophenyl)ethanone (iva, 1481.0 g, 6836.3 mmol) was dissolved in toluene (6 L). 1,2-Ethanediol (953 ml, 17100 mmol) and p-toluenesulfonic acid monohydrate (104 g, 547 mmol) were added to the solution. The reaction mixture was heated to reflux at 104 to 110°C using a Dean-Stark trap to remove water for 17.4 hours. HPLC analysis indicated that 37% of the starting material remained unreacted. About 600 ml of distillate was removed and the reaction mixture was heated under reflux for an additional 5 hours (total of 22 hours). HPLC analysis indicated no further reaction.

[00323] It was speculated that residual K2CO3 in the starting material compound iv-a may have stopped the reaction. Therefore, the reaction mixture was cooled to room temperature and washed with 1N aqueous hydrochloric acid (3 x 6.66 L). After the aqueous acid wash, the organic layer was transferred back to the reaction vessel. 1,2-Ethanediol (381 ml, 6840 mmol) and p-toluenesulfonic acid monohydrate (104 g, 547 mmol) were added and the reaction mixture was heated under reflux for 16 hours. HPLC analysis indicated that about 20% of the starting material remained unreacted. About 100 ml of the distillate was removed. 1,2-Ethanediol (380 ml, 6800 mmol) was added and refluxed for 6 hours (22 hours total). HPLC indicated that 7% of the starting material remained unreacted. About 125 ml of the distillate was removed. The reaction mixture was heated to reflux for 6 hours (28 hours total). HPLC indicated that 5.4% of the starting material remained unreacted. About 125 ml of the distillate was removed. The reaction mixture was heated to reflux for an additional 7 hours. HPLC analysis indicated that 3.5% of the starting material remained unreacted. About 80 ml of the distillate was removed. The reaction was considered complete at this point.

[00324] The reaction mixture was washed with a 1 N aqueous sodium hydroxide solution (2 x 5.5 L). The first basic wash was extracted with toluene (2.1 L). The combined toluene solution was washed with water (7 L) and concentrated to yield 2153 g dark oil. HPLC analysis indicated 93.8% product purity with 1.90% starting material and 0.79% de-iodine product. 1 H NMR analysis indicated that about 0.5 equivalent of toluene (about 256 g) remained in the product. The corrected yield of compound va was 88.0%. 1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 8.8 Hz, 1H), 6.70 (d, J = 11.0 Hz, 1H), 4.17 and 3.92 (m, 4H), 3.91 and 3.80 (m, 2H), 1.75 (s, 3H), 1.46 (t, J = 7, 0Hz, 3H). STEP 3. 3-CHLORO-6-ETHOXY-2-FLUORO-5-(2-METHYL-1,3-DIOXOLAN-2-IL)BENZALDEHYDE (VI)

[00325] Into an oven-dried 3-liter 4-neck round bottom flask equipped with an overhead stirrer, a 500 ml addition funnel, nitrogen inlet, septa, and thermocouple was charged N,N-diisopropylamine (87.8 ml, 626 mmols) and anhydrous tetrahydrofuran (1090 ml, 13500 mmols). This solution was cooled to -72 °C and charged with 2.5 M n-butyllithium in hexanes (261 ml, 652 mmol). The n-butyllithium solution was added over 18 minutes. The maximum internal temperature during the addition was -65°. The dry ice-acetone bath was replaced with an ice-water bath and the reaction mixture was warmed to about -5°C to about 0°C and held for 15 minutes. The reaction mixture was then cooled to -74.5°C.

[00326] To a separate 1 liter round bottom flask containing 2-(5-chloro-2-ethoxy-4-fluorophenyl)-2-methyl-1,3-dioxolane (v-a, 136.1 g, 522.1 mmol) was added anhydrous tetrahydrofuran (456 ml) to dissolve the solids. The resulting solution was cooled in an ice bath to about 0°C. The solution containing compound v-a was transferred to the LDA solution for 40 minutes through a cannula while maintaining the reaction temperature between -70°C and -72.5°C. The reaction mixture becomes a yellow aqueous slurry and was stirred for 37 minutes at -74°C. N,N-Dimethylformamide (60.6 ml, 783 mmol) was charged in one portion via syringe and this addition produced an exotherm from -74.5°C to -66.5°C. The reaction was monitored by HPLC at 90 minutes after addition. Starting material was present at 2.9%. The cold bath was removed and the reaction mixture was warmed to room temperature. The reaction mixture was sampled and analyzed after 3 hours and unreacted starting material was present at 1.5%. The reaction was considered complete and was quenched by adding the reaction solution to cold water (1.4 L) and diluted with ethyl acetate (1.5 L). The aqueous layer was extracted with ethyl acetate (1.5 L) and the organic layers were combined and washed with brine (20 wt% aqueous NaCl, 2 x 600 mL) and dried over anhydrous MgSO 4 . The MgSO4 was filtered off and the filtrate was concentrated to an oil with some solids present. This residue was dissolved in methylene chloride and loaded onto a silica gel pad (586 g). The silica pad was eluted with 2% EtOAc/DCM (monitored by TLC using 100% DCM as eluent). The desired fractions were collected and concentrated under reduced pressure to yield a light amber oil. The oil was placed under high vacuum to yield compound vi as a yellow solid (146.5 g, 95.1% yield). 1H NMR (400 MHz, CDCl3) δ 10.27 (s, 1H), 7.78 (d, J = 8.5 Hz, 1H), 4.10 and 3.96 (m, 4H), 3.87 and 3.76 (m, 2H), 1.72 (s, 3H), 1.44 (t, J = 7.0 Hz, 3H). LCMS for C13H15ClFO4 (M + H)+: m/z = 289.1.

STEPS 4-10. (R)-4-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((R)-1-HYDROXYETHYL)PHENYL)PYRROLIDIN-2-ONE (XIII)

[00327] The title compound was prepared using procedures analogous to those described in Example 1, Steps 6 to 12. EXAMPLE 3. (R)-4-(3-((S)-1-(4-AMINO-3-METHYL-1H-PYRAZO[3,4-D]PYRIMIDIN-1-YL)ETHYL)-5-CHLORO-2-ETHOXY-6-FLUO ROFENIL)PYRROLIDIN-2-ONE STEP 1. (R)-1-(5-CHLORO-2-ETHOXY-4-FLUORO-3-((R)-5-OXOPYRROLIDIN-3-YL)PHENYL)ETHYL METANOSULFONATE (XIV)

[00328] (R)-4-(3-Chloro-6-ethoxy-2-fluoro-5-((R)-1-hydroxyethyl)phenyl)pyrrolidin-2-one (xiii, 172.0 g, 570.0 mmol) (consisted of 147 g at 99.83%: 0.09% chiral purity, 99.33% chemical purity; and 25 g, 87.46%: 12.54% chiral purity, 86.74% chemical purity) was dissolved in methylene chloride (860 ml). N,N-diisopropylethylamine (149 ml, 855 mmol) was added to the solution from about -7°C to about 2°C. Methanesulfonyl chloride (57.4 mL, 741 mmol) was added dropwise to the reaction mixture over 25 minutes. The suspension turned into a clear solution. At the 30 minute reaction time point, HPLC indicated that the reaction was complete. This reaction mixture containing compound xiv was used directly in the next reaction. STEP 2. (R)-4-(3-CHLORO-6-ETHOXY-2-FLUORO-5-((S)-1- HYDRAZINYLETHYL)PHENYL)PYRROLIDIN-2-ONE (XV)

[00329] At 0°C, hydrazine (178.9 ml, 5.7 mol) was added in one portion followed by N-methylpyrrolidinone (860 ml) to the reaction mixture containing compound xiv from Step 1. The reaction mixture became cloudy and some precipitates formed. The mixture was heated to 40 to 57°C under nitrogen for 90 minutes. HPLC indicated that all the mesylate was consumed.

[00330] The reaction mixture was cooled to room temperature and a saturated solution of sodium bicarbonate (28.3 g) in water (300 ml) was added. The mixture was stirred for 20 minutes, at which time dichloromethane (300ml) was added. The organic layer was separated and stirred with a solution of sodium bicarbonate (14.2g) in water (150ml). The aqueous layer was extracted with dichloromethane (200 ml x 2). The combined organic layers were washed with brine (80 ml), dried over anhydrous Na 2 SO 4 (311 g), concentrated and azeotroped with toluene (250 ml) to yield a colorless N-methylpyrrolidinone solution containing compound xv which was used directly in the next reaction. A sample was purified for NMR analysis. 1H NMR (400 MHz, DMSO-d6), δ 7.88 (s, 1H), 7.66 (d, J = 8.5 Hz, 1H), 4.42 (q, J = 6.7 Hz, 1H), 4.06 and 3.88 (m, 2H), 3.79 and 3.66 (m, 1H), 3.65 and 3.51 ( m, 1H), 3.24 (t, J = 8.8 Hz, 1H), 2.60 and 2.46 (m, 1H), 2.36 and 2.25 (m, 1H), 1.37 (t, J = 6.9 Hz, 3H), 1.26 (d, J = 6.8 Hz, 3H). LCMS for C14H19ClFN3O2 (M + H)+: m/z = 316.1. STEP 3. 5-AMINO-1-((S)-1-(5-CHLORO-2-ETHOXY-4-FLUORO-3-((R)-5-OXOPYRROLIDIN-3-YL)PHENYL)ETHYL)-3-METHYL-1H-PYRAZOL-4-CARBONITRILE (XVI)

[00331] With stirring, (1-ethoxyethylidene)malononitrile (101 g, 741 mmol) was added to the N-methylpyrrolidinone solution of compound xv from Step 2 in portions and the mixture was stirred at room temperature under nitrogen. After 15 minutes, HPLC analysis indicated 11% hydrazine starting material, compound xv, relative to product compound xvi. N,N-Diisopropylethylamine (15 ml, 86 mmol) was added and the reaction mixture was stirred at room temperature for 15 hours. HPLC analysis indicated that 5.6% starting material remained. N,N-Diisopropylethylamine (5 ml, 30 mmol) was added and the reaction mixture was stirred at room temperature for 5 hours. HPLC indicated that 5.6% starting material remained. The reaction mixture was stirred for 2.5 days and combined with two similar batches and worked together.

[00332] The reaction mixtures of three batches of compound xvi were combined. Aqueous 0.5 M sodium hydroxide solution (3.8 L) was added at 10 to 20°C and stirred for 5 minutes. HPLC indicated that all of the (1-ethoxyethylidene)malononitrile starting material was consumed. Ethyl acetate (4.0 L) was added and the mixture stirred for 15 minutes. The layers have been separated. The organic layer was washed with 0.5M sodium hydroxide in water (2.38 L). The layers have been separated. The combined aqueous layer was extracted with ethyl acetate (2 x 2 L). The combined organic layers were washed with 1.0 M aqueous hydrochloric acid (3.56 L) and the pH of the resulting aqueous layer was 2 to 3. The organic layer was washed with brine (5 L), dried over anhydrous Na 2 SO 4 , concentrated and dried under high vacuum for 40 hours to yield compound xvi as a light brown foamy solid (702.7 g). 1H NMR (500 MHz, DMSO and d6) δ 7.78 (s, 1H), 7.44 (d, J = 8.4 Hz, 1H), 6.53 (s, 2H), 5.64 (q, J = 6.7 Hz, 1H), 3.96 (m, 1H), 3.74 (m, 1H), 3.34 (m, 1H), 3.58 (m, 2H), 2.59 and 2.50 (m, 1H), 2.29 (m, 1H), 2.04 (s, 3H), 1.57 (d, J = 6.8 Hz, 3H), 1.37 (t, J = 6.9 Hz, 3H). LCMS for C19H22ClFN5O2 (M + H)+: m/z = 406.1.

[00333] The overall yield of three steps of compound xvi (mesylation, hydrazinolysis and pyrazole formation) was calculated as 72.8% of the total input of compound xiii. Purity was determined by HPLC to be about 80%. HPLC analysis indicated some product existing in the basic aqueous layer which was subsequently extracted with EtOAc (2 L), washed with 1.0 M aqueous hydrochloric acid and brine, dried over anhydrous sodium sulfate, concentrated and dried on a high vacuum pump for 40 hours to afford compound xvi as a brown oil (134 g, 13.9%). STEP 4. (R)-4-(3-((S)-1-(4-AMINO-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)ETHYL)-5-CHLORO-2-ETHOXY-6-FLUOROPHENYL)PYRROLIDIN-2-ONE (XVII)

[00334] 5-Amino-1-((S)-1-(5-chloro-2-ethoxy-4-fluoro-3-((R)-5-oxopyrrolidin-3-yl)phenyl)ethyl)-3-methyl-1H-pyrazole-4-carbonitrile (xvi, 702.7 g, 1731 mmol) was added to a reaction vessel with formadin acetate (1802 g, 17 .31 mol) and 1,2-ethanediol (3.51 L). The reaction mixture was heated at 102 to 103°C with stirring for 18 hours. The reaction mixture was cooled to room temperature and ethyl acetate (7 L) and water (6 L) were added and the biphasic mixture stirred for 15 minutes. The organic layer was separated and the aqueous layer was diluted with more water (4.5 L) and ethyl acetate (3 L) and stirred for 10 minutes. The organic layer was separated. The aqueous layer was further extracted with ethyl acetate (2 L). The organic layers were combined and stirred with water (4.5 L). The aqueous layer was separated and the organic layer was filtered through a pad of celite (about 1 kg). The organic layer was extracted with 1.0M aqueous hydrochloric acid (7 L) by stirring the mixture for 10 minutes. The aqueous layer was separated. The light brown organic layer was stirred with additional 1.0 M aqueous hydrochloric acid (3 L) for 10 minutes. The aqueous layer was separated. The aqueous acidic layers were combined and washed with toluene (500ml). The aqueous acidic solution was cooled with an ice water bath and methylene chloride (4 L) was added. At 5 to 15°C, a solution of sodium hydroxide (530 g) in water (530 ml) (50% NaOH solution) was slowly added to a solution pH of 11 to 12. Solid precipitates were observed. Additional methylene chloride (3.5 L) and methanol (300 ml) were added and the mixture stirred for 10 to 15 minutes. The solid product was collected by filtration and dried on the filter under suction for 16 hours to yield compound xvii (289.7 g) as a brown solid. 1H NMR (400 MHz, DMSO and d6) δ 8.11 (s, 1H), 7.82 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.30 (br s, 2H), 6.23 (q, J = 7.0 Hz, 1H), 3.97 (p, J = 9.2 Hz, 1H), 3.90 and 3.73 (m, 2H), 3.57 (t, J = 9.9 Hz, 1H), 3.25 (dd, J = 9.2, 8.7 Hz, 1H), 2.48 (s, 3H), 2.60 and 2.50 (m, 1H), 2.36 and 2.20 (m, 1H), 1.69 (d, J = 7.1 Hz, 3H), 1.39 (t, J = 6.9 Hz, 3H). LCMS for C20H23ClFN6O2 (M + H)+: m/z = 433.3.

[00335] The filtrate was transferred to a separatory funnel and the organic layer was separated. The aqueous layer was stirred with methylene chloride (5 L) and methanol (200 ml). The combined organic layer was dried over anhydrous sodium sulfate, concentrated, dried on a high vacuum pump for 16 hours to yield an additional 259.3 g as a brown solid. The total yield of xvii was 548.3g in 73.2% yield. STEP 5. (R)-4-(3-((S)-1-(4-AMINO-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)ETHYL)-5-CHLORO-2-ETHOXY-6-FLUOROPHENYL)PYRROLIDIN-2-ONE (XVIII)

[00336] A 1.0 M aqueous hydrochloric acid solution (HCl, 5.0 L, 5.0 mol) was added to (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one (xvi i, 609.8 g, 1.409 mol) at room temperature. The resulting thick aqueous slurry was then heated to 50°C to provide a clear solution. An additional 1.82 L of 1.0 M aqueous hydrochloric acid solution (HCl, 1.82 L, 1.82 mol; total 6.82 L, 6.82 mol, 4.84 equiv) was added to the clear solution at 50°C and the solution was then filtered through a filter at approximately 50°C. The filtered reaction mixture was gradually cooled to room temperature over 2 hours before being further cooled to 0 to 5°C. The reaction mixture was stirred at 0 to 5°C for at least 20 minutes to initiate precipitation. The resulting solids were collected by filtration, rinsed with a portion of the cold mother liquor, followed by 1.0 M aqueous hydrochloric acid (HCl, 200 ml) and dried on the filter funnel at room temperature under suction to constant weight (about 39 hours) to provide the hydrochloric acid salt of the compound of Formula I: (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyra) hydrochloride zolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one (xviii, 348.7 g, 661.2 g theoretical, 52.7%) as white crystalline powder. 1H NMR (400 MHz, DMSO-d6) δ 9.39 (br s, 1H), 9.05 (br s, 1H), 8.50 (s, 1H), 7.84 (s, 1H), 7.59 (d, J = 8.4 Hz, 1H), 6.28 (q, J = 6.9 Hz, 1H), 3.95 (m, 1H), 3.79 (m, 2H), 3.55 (m, 1H), 3.22 (m, 1H), 2.59 (s, 3H), 2.55 (ddd, J = 16.8, 10.3, 2.3 Hz, 1H), 2.28 (ddd, J = 16.8, 8.6, 1.5 Hz, 1H), 1.7 3 (d, J = 7.0 Hz, 3H), 1.38 (t, J = 6.9 Hz, 3H) ppm. 13C NMR (100 MHz, DMSO and d6) δ 175.3, 156.4 (JCF = 249.8 Hz), 153.8 (JCF = 7.0 Hz), 152.4, 150.8, 147.3, 144.3, 131.4 (JCF = 3.5 Hz), 127.3, 126, 4 (JCF = 12.6 Hz), 116.1 (JCF = 18.4 Hz), 98.0, 72.1, 49.1, 46.6, 36.0, 29.4, 21.0, 15.4, 14.6 ppm. 19F NMR (376 MHz, DMSO-d6) δ - 113.6 (d, JFH = 7.7 Hz) ppm. C20H23Cl2FN6O2 (MW 469.34); LCMS (EI) m/e 433.2 (M+ + H; exact mass of xvii: 432.15). Water content by KF: 3.63% by weight; chloride (Cl-) content by titration: 7.56% by weight (7.56% by theory).

[00337] The melting/decomposition range of crystalline form of (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloride salt was determined by DSC, from an initial temperature of 30°C to a final temperature of 350°C using a heating rate of 10°C/min. The DSC thermogram revealed an endothermic event with an onset at 194.37°C and a peak at 206.55°C, as shown in Figure 1.

[00338] TGA thermogram showed total weight loss of 4.3% up to 210°C. Above 210°C, salt begins to decompose, as shown in Figure 2.

[00339] A representative X-Ray Powder Diffraction (XRPD) pattern is shown in Figure 3 and Table 2 shows the peaks and corresponding intensities. TABLE 2 EXAMPLE 4. ALTERNATIVE SYNTHESIS OF (R)-4-(3-((S)-1-(4-AMINO-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)ETHYL)-5-CHLORO-2-ETHOXY-6-FLUOROPHENYL)PYRROLIDIN-2-ONE STEP 1. (R)-4-(3-ACETYL-5-CHLORO-2-ETHOXY-6- FLUOROPHENYL)PYRROLIDIN-2-ONE (XIX)

[00340] (4R)-4-[3-chloro-6-ethoxy-2-fluoro-5-(1-hydroxyethyl)phenyl]pyrrolidin-2-one (as a mixture of two diastereomers with R-configuration in the pyrrolidinone and R- or S-configurations in the secondary alcohol) (xiii, 16.7 g, 55.3 mmol) was dissolved in dichloromethane (167 mL). The solution was cooled in an ice water bath and Dess-Martin periodinane (35.2 g, 83.0 mmol) was added in small portions. The reaction mixture was stirred at room temperature for 2 hours, at which time HPLC analysis showed completion of reaction. A solution of sodium sulphite (28 g, 220 mmol) in water (70 ml) was added to the reaction mixture and the mixture was stirred for 20 minutes. A 1.0 M sodium hydroxide solution was added to the mixture and stirred for 10 minutes. The layers were allowed to settle and the organic layer was separated and washed sequentially with 1M aqueous sodium hydroxide solution (66 ml) and water (60 ml). The organic layer was dried over anhydrous sodium sulfate. The drying agent was removed by filtration and the filtrate was concentrated to yield (R)-4-[3-acetyl-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one as an oil which was used in the next reaction without further purification. STEP 2. (R,E)-TERT-BUTYL 2-(1-(5-CHLORO-2-ETHOXY-4-FLUORO-3-(5-OXOPYRROLIDIN-3-IL)PHENYL)ETHYLIDENE)HYDRAZINECARBOXYLATE (XX)

[00341] Crude (R)-4-[3-acetyl-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one (compound xix from Step 1) was dissolved in methanol (60 mL) and t-butyl carbazate (8.04 g, 60.8 mmol) was added to the solution. The reaction mixture was stirred at 65°C for 3.5 days, at which time HPLC analysis showed completion of the reaction. The mixture was concentrated under reduced pressure and the residue was purified by chromatography on silica gel eluting with a mixture of 0 to 5% methanol in ethyl acetate to yield (R,E)-tert-butyl 2-(1-(5-chloro-2-ethoxy-4-fluoro-3-(5-oxopyrrolidin-3-yl)phenyl)ethylidene)hydrazinecarboxylate (xx, 19.5 g, 85 %). 1H NMR (500 MHz, DMSO-d6) δ 9.83 (s, 1H), 7.78 (s, 1H), 7.36 (d, J = 8.6 Hz, 1H), 4.07 (p, J = 9.1 Hz, 1H), 3.84 and 3.69 (m, 2H), 3.59 (t, J = 9.5 Hz, 1H), 3.28 (t, J = 9.5 Hz, 1H), 2.54 (m, 1H), 2.33 (m, 1H), 2.14 (s, 3H), 1.46 (s, 9H), 1.25 (t, J = 7.0 Hz, 3H). LCMS for C19H25ClFN3NaO4 (M + Na)+: m/z = 436.1. STEP 3. TERC-BUTYL 2-((S)-1-(5-CHLORO-2-ETHOXY-4-FLUORO-3-((R)-5-OXOPYRROLIDIN-3-YL)PHENYL)ETHYL)HYDRAZINECARBOXYLATE (XXI)

[00342] (R,E)-tert-Butyl 2-(1-(5-chloro-2-ethoxy-4-fluoro-3-(5-oxopyrrolidin-3-yl)phenyl)ethylidene)hydrazinecarboxylate (xx, 0.5 g, 1.2 mmol) was dissolved in methanol (25 ml) and the solution was bubbled with nitrogen gas for 5 minutes. Bis(1,5-cyclooctadiene)rhodium(I)tetrafluoroborate (35 mg, 0.086 mmol) and (R)-(-)-1-{(S)-2-[bis(4-trifluoromethylphenyl)phosphine]ferrocenyl}ethyl-di-t-butylphosphine (64 mg, 0.094 mmol) were added to the solution and the resulting reaction mixture was bubbled with nitrogen gas for 30 minutes . The reaction mixture was then stirred under hydrogen gas pressure (0.38 MPa (56 psi)) for 2.5 days. The reaction mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography on silica gel eluting with a mixture of methanol (0 to 10%) in ethyl acetate. The desired fractions were concentrated to yield tert-butyl 2-((S)-1-(5-chloro-2-ethoxy-4-fluoro-3-((R)-5-oxopyrrolidin-3-yl)phenyl)ethyl)hydrazinecarboxylate (xxi, 428 mg, 85% yield). 1H NMR (500 MHz, DMSO and d6) δ 8.18 (s, 1H), 7.78 (s, 1H), 7.53 (d, J = 8.2 Hz, 1H), 4.73 (s, 1H), 4.41 (br s, 1H), 3.98 (m, 1H), 3.75 (m, 2H), 3.61 (m , 1H), 3.26 (m, 1H), 2.53 (m, 1H), 2.29 (dd, J = 17.6, 8.6 Hz, 1H), 1.32 (s, 12H), 1.10 (d, J = 6.5 Hz, 1H). LCMS for C19H27ClFN3NaO4 (M + Na)+: m/z = 437.9. Analysis by chiral HPLC indicated that the product contained the desired diastereomer 85.6% tert-butyl-2-((S)-1-(5-chloro-2-ethoxy-4-fluoro-3-((R)-5-oxopyrrolidin-3-yl)phenyl)ethyl)hydrazine carboxylate (xxi) and the undesired tert-butyl-2-((R)-1-(5-chloro) 14.3% -2-ethoxy-4-fluoro-3-((R)-5-oxopyrrolidin-3-yl)phenyl)ethyl)hydrazinecarboxylate. STEP 4. 5-AMINO-1-((S)-1-(5-CHLORO-2-ETHOXY-4-FLUORO-3-((R)-5-OXOPYRROLIDIN-3-YL)PHENYL)ETHYL)-3-METHYL-1H-PYRAZOL-4-CARBONITRILE (XVI)

[00343] tert-Butyl 2-((S)-1-(5-Chloro-2-ethoxy-4-fluoro-3-((R)-5-oxopyrrolidin-3-yl)phenyl)ethyl)hydrazinecarboxylate (xxi, 130 mg, 0.31 mmol) and p-toluenesulfonic acid monohydrate (86 mg, 0.45 mmol) were added to ethanol (3 ml) and the reaction mixture was heated at 50 °C for 20 hours. HPLC analysis showed that there was about 88% unreacted starting material. An additional amount of p-toluenesulfonic acid (86 mg, 0.45 mmol) was charged and the reaction mixture was heated to 60°C for 24 hours. HPLC analysis showed complete Boc-deprotection. This reaction mixture was added with (1-ethoxyethylidene)malononitrile (61 mg, 0.45 mmol) and N,N-diisopropylethylamine (260 µl, 1.5 mmol). The reaction mixture was stirred at room temperature for 2 hours. HPLC showed completion of pyrazole ring formation. A 1.0 M aqueous sodium hydroxide solution was added to the reaction mixture and stirred for 20 minutes. Ethyl acetate (20 ml) was added to the mixture and stirred. The biphasic mixture was allowed to settle. The ethyl acetate layer was collected and the aqueous layer was extracted with ethyl acetate (10 ml). The combined ethyl acetate solution was added with 1M aqueous hydrochloric acid (5 ml) and stirred for 15 minutes. The biphasic mixture was allowed to settle and the organic layer was collected and dried over anhydrous sodium sulfate. Sodium sulfate was removed by filtration and the filtrate was concentrated to yield 5-amino-1-((S)-1-(5-chloro-2-ethoxy-4-fluoro-3-((R)-5-oxopyrrolidin-3-yl)phenyl)ethyl)-3-methyl-1H-pyrazole-4-carbonitrile (xvi, 126 mg, quantitative yield of crude product) and was used in the next step without further purification. STEP 5. (R)-4-(3-((S)-1-(4-AMINO-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)ETHYL)-5-CHLORO-2-ETHOXY-6-FLUOROPHENYL)PYRROLIDIN-2-ONE (XVII)

[00344] 5-Amino-1-{(1S)-1-[5-chloro-2-ethoxy-4-fluoro-3-(5-oxopyrrolidin-3-yl)phenyl]ethyl}-3-methyl-1H-pyrazole-4-carbonitrile (xvi, 126 mg, 0.31 mmol) was added withformamidine acetate (323 mg, 3.1 mmol) and 1,2-ethanediol (2ml). The reaction mixture was heated to 104 to 105°C with stirring. After 18 hours, HPLC analysis showed about 44% starting material compound xvi remaining. The reaction mixture was heated to 115°C for 24 hours. HPLC analysis showed the reaction was complete. The reaction mixture was cooled to room temperature and ethyl acetate (10 ml) and water (5 ml) were added. The biphasic mixture was stirred. The layers were allowed to separate. The organic layer was collected and the aqueous layer was extracted with ethyl acetate (5 ml). The combined ethyl acetate solution was washed with water (5 ml), dried over anhydrous sodium sulfate. Sodium sulfate was filtered off and the filtrate was concentrated to a residue. The residue was purified by silica gel chromatography. The column was eluted with a mixture of methanol (0 to 5%) in methylene chloride. The desired fractions were combined and evaporated to yield (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one (xvii, 94 mg, 69.9% yield). 1H NMR (400 MHz, DMSO and d6) δ 8.11 (s, 1H), 7.82 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.30 (br s, 2H), 6.23 (q, J = 7.0 Hz, 1H), 3.97 (p, J = 9.2 Hz, 1H), 3.90 and 3.73 (m, 2H), 3.57 (t, J = 9.9 Hz, 1H), 3.25 (dd, J = 9.2, 8.7 Hz, 1H), 2.48 (s, 3H), 2.60 and 2.50 (m, 1H), 2.36 and 2.20 (m, 1H), 1.69 (d, J = 7.1 Hz, 3H), 1.39 (t, J = 6.9 Hz, 3H). LCMS for C20H23ClFN6O2 (M + H)+: m/z = 433.3.

[00345] Analysis by chiral HPLC of the product indicated that it contained the desired diastereomer, (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one (xvii), at 87% and the undesired diastereomer (R 13% )-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one.

STEP 6. (R)-4-(3-((S)-1-(4-AMINO-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)ETHYL)-5-CHLORO-2-ETHOXY-6-FLUOROPHENYL)PYRROLIDIN-2-ONE

[00346] The title product was prepared according to the procedure described in Example 3, Step 5. The resulting hydrochloride salt is well compatible with material made from the synthetic process described in Example 3, comparable in every aspect including chemical purity, chiral purity and solid state characteristics.

EXAMPLE A1: PI3K ENZYME ASSAY

[00347] The PI3-kinase luminescent assay kit including lipid kinase substrate, Protective Protein D-myo-phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)D (+)-sn-1,2-di-O-octanoylglyceryl, linked 3-O-phospho (PIP2), biotinylated I(1,3,4,5)P4 , PI(3,4,5)P3 is purchased from Echelon Biosciences (Salt Lake City, UT, USA). The AlphaScreenTM GST Detection Kit including donor and recipient microspheres was purchased from PerkinElmer Life Sciences (Waltham, MA). PI3Kδ (p110δ /p85α) is purchased from Millipore (Bedford, MA). ATP, MgCl2, DTT, EDTA, HEPES, and CHAPS are purchased from Sigma-Aldrich (St. Louis, MO).

ALPHASSCREENTM ASSAY FOR PI3Kδ

[00348] The kinase reaction is conducted in a Thermo Fisher Scientific 384-well REMP plate in a final volume of 40 µl. Inhibitors are first serially diluted in DMSO and added to plate wells prior to addition of other reaction components. The final concentration of DMSO in the assay is 2%. PI3K assays are performed at room temperature in 50 mM HEPES, pH 7.4, 5 mM MgCl2, 50 mM NaCl, 5 mM DTT, and 0.04% CHAPS. Reactions are initiated by the addition of ATP, the final reaction mix consisting of 20 µM PIP2, 20 µM ATP, 1.2 nM PI3Kδ are incubated for 20 minutes. 10 µl of reaction mixture is then transferred to 5 µl of 50 nM biotinylated I(1,3,4,5)P4 in quenched buffer: 50 mM HEPES pH 7.4, 150 mM NaCl, 10 mM EDTA, 5 mM DTT, 0.1% Tween-20, followed by the addition of 10 µl of microspheres AlphaScreenTM donor and recipient samples suspended in quenched buffer containing 25 nM PI(3,4,5)P3 detector protein. The final concentration of donor and recipient microspheres is 20 mg/ml. After plate sealing, the plate is incubated in the dark at room temperature for 2 hours. Product activity is determined on a Fusion-alpha microplate reader (Perkin-Elmer). IC50 determination is performed by fitting the percent control activity curve versus inhibitor concentration recording using GraphPad Prism 3.0 software.

EXAMPLE A2: PI3K ENZYME ASSAY

[00349] Materials: Lipid kinase substrate, phosphoinositol-4,5-bisphosphate (PIP2), are purchased from Echelon Biosciences (Salt Lake City, UT, USA). PI3K α, β, δ and Y isoforms are purchased from Millipore (Bedford, MA, USA). ATP, MgCl2, DTT, EDTA, MOPS and CHAPS are purchased from Sigma-Aldrich (St. Louis, MO, USA).

[00350] Kinase reactions are conducted in Thermo Fisher Scientific 96-well clear bottom plate in a final volume of 24 μl. Inhibitors are first serially diluted in DMSO and added to plate wells prior to addition of other reaction components. The final concentration of DMSO in the assay is 0.5%. PI3K assays are performed at room temperature in 20 mM MOPS, pH 6.7, 10 mM MgCl2, 5 mM DTT, and 0.03% CHAPS. The reaction mixture is prepared containing 50 µM PIP2, kinase and varying concentration of inhibitors. Reactions are initiated by adding ATP containing 2.2 μCi [Y-33P]ATP to a final concentration of 1000 μM. The final concentration of α, β, δ and y PI3K isoforms in the assay were 1.3, 9.4, 2.9 and 10.8 nM, respectively. Reactions are incubated for 180 minutes and terminated by the addition of 100 µl of 1 M potassium phosphate pH 8.0, 30 mM EDTA quench buffer. A 100 µl aliquot of the reaction solution is then transferred to a 96-well Millipore MultiScreen IP 0.45 µm PVDF filter plate (the filter plate is pre-wetted with 200 µl 100% ethanol, distilled water and 1 M potassium phosphate pH 8.0, respectively). The filter plate is aspirated into Millipore Tubing under vacuum and washed with 18 x 200 µl of wash buffer containing 1 M potassium phosphate pH 8.0 and 1 mM ATP. After aspiration drying and blotting, the plate is air dried in a 37°C incubator overnight. A Packard TopCount adapter (Millipore) is then attached to the plate followed by the addition of 120 µl of Microscint 20 scintillation cocktail (Perkin Elmer) to each well. After sealing the plate, the radioactivity of the product is determined by scintillation counting in Topcount (Perkin-Elmer). IC50 determination is performed by fitting the percent control activity curve versus inhibitor concentration recording using GraphPad Prism 3.0 software.

[00351] (R)-4-(3-((S)-1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloric acid salt was tested in the assay of Example A2 and determined as a selective inhibitor for PI3Kδ.

[00352] (R)-4-(3-((S)-1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloric acid salt was tested in the assay of Example A2 and determined to be a >100-fold selective inhibitor for PI3Kδ relative to each of PI3Kα, PI3Kβ and PI3KY.

EXAMPLE A3: PI3Kδ SPARKLING PROXIMITY ASSAY MATERIALS

[00353] [Y-33P]ATP (10mCi/ml) was purchased from Perkin-Elmer (Waltham, MA). Lipid kinase substrate, D-myo-phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)D (+)-sn-1,2-di-O-octanoylglyceryl, linked 3-O-phospho (PIP2), CAS 204858-53-7, was purchased from Echelon Biosciences (Salt Lake City, UT, USA). PI3Kδ (p110δ /p85α) was purchased from Millipore (Bedford, MA). ATP, MgCl2, DTT, EDTA, MOPS and CHAPS were purchased from Sigma-Aldrich (St. Louis, MO, USA). Wheat Germ Agglutinin (WGA) YSi SPA Scintillation Microspheres were purchased from GE healthcare life sciences (Piscataway, NJ, USA).

[00354] The kinase reaction was conducted in Thermo Fisher Scientific polystyrene white 384-well matrix plate in a final volume of 25 µl. Inhibitors were first serially diluted in DMSO and added to plate wells prior to addition of other reaction components. The final concentration of DMSO in the assay was 0.5%. PI3K assays were performed at room temperature in 20 mM MOPS, pH 6.7, 10 mM MgCl2, 5 mM DTT, and 0.03% CHAPS. Reactions were initiated by the addition of ATP, the final reaction mixture consisted of 20 µM PIP2, 20 µM ATP, 0.2 µCi [y-33P] ATP, 4 nM PI3Kδ. The reactions were incubated for 210 minutes and terminated by the addition of 40 μl of SPA microspheres suspended in briskly cooled buffer: 150 mM potassium phosphate pH 8.0, 20% glycerol. 25 mM EDTA, 400 µM ATP. The final concentration of SPA microspheres was 1.0 mg/ml. After plate sealing, plates were shaken overnight at room temperature and centrifuged at 1800 rpm for 10 minutes, product radioactivity was determined by scintillation counting in Topcount (Perkin-Elmer). IC50 determination was performed by fitting the percent control activity curve versus inhibitor concentration recording using GraphPad Prism 3.0 software. The compound of Formula I was found to have an IC50 of < 10 nM in the assay of Example A3.

EXAMPLE B1: B CELL PROLIFERATION ASSAY

[00355] To acquire B cells, human PBMC is isolated from the peripheral blood of normal drug-free donors by standard density gradient centrifugation in Ficoll-Hypague (GE Healthcare, Piscataway, NJ, USA) and incubated with anti-CD19 microbeads (Miltenyi Biotech, Auburn, CA, USA). B cells are then purified by positive immunostaining using an autoMacs (Miltenyi Biotech) according to the manufacturer's instructions.

[00356] Purified B cells (2x10 5 /well/200 µl) are cultured in 96-well ultra-low binding plates (Corning, Corning, NY, USA) in RPMI1640, 10% FBS and goat anti-human F(ab')2 IgM (10 µg/ml) (Invitrogen, Carlsbad, CA, USA) in the presence of different amount of test compounds for three days. [ 3 H]-thymidine (1 µCi/well) (PerkinElmer, Boston, MA) in PBS is then added to the B cell cultures for an additional 12 hours before the incorporated radioactivity is separated by filtration with water through GF/B filters (Packard Bioscience, Meriden, CT) and measured by liquid scintillation counting with a TopCount (Packard Bioscience).

EXAMPLE B2: PFEIFFER CELL PROLIFERATION ASSAY

[00357] Pfeiffer cell line (diffuse large B-cell lymphoma) is purchased from the ATCC (Manassas, VA, USA) and maintained in the recommended culture medium (RPMI and 10% FBS). To measure the anti-proliferation activity of the compounds, Pfeiffer cells are plated with the culture medium (2x10 3 cells/well/per 200 µl) in 96-well ultra-low binding plates (Corning, Corning, NY, USA), in the presence or absence of a range of test compound concentrations. After 3 to 4 days, [ 3 H]-thymidine (1 µCi/well) (PerkinElmer, Boston, MA) in PBS is then added to the cell culture for an additional 12 hours before the incorporated radioactivity is separated by filtration with water through GF/B filters (Packard Bioscience, Meridenj, CT) and measured by liquid scintillation counting with a TopCount (Packard Bioscience).

EXAMPLE B3: SUDHL-6 CELL PROLIFERATION ASSAY

[00358] SUDHL-6 cell line (diffuse large B-cell lymphoma) was purchased from the ATCC (Manassas, VA, USA) and maintained in the recommended culture medium (RPMI and 10% FBS). To measure the anti-proliferation activity of the compounds through ATP quantitation, SUDHL-6 cells were plated with the culture medium (5000 cells/well/per 200 µl) in 96-well clear black polystyrene tissue culture plate (Greiner-bio-one by VWR, NJ) in the presence or absence of a concentration range of test compounds. After 3 days, a Cell Titer-GLO Luminescent cell culture agent (Promega, Madison, WI) was added to each well for 10 minutes at room temperature to stabilize the luminescent signal. This determines the number of viable cells in the culture based on the quantification of ATP present, which signals the presence of metabolically active cells. Luminescence was measured with the TopCount 384 (Packard Bioscience by Perkin Elmer, Boston, MA).

EXAMPLE C: AKT PHOSPHORYLATION ASSAY

[00359] Branch cells (Burkitts lymphoma B lymphocyte) are obtained from the ATCC (Manassas, VA, USA) and maintained in RPMI1640 and 10% FBS. Cells (3x10 7 cells/tube/3 ml in RPMI) are incubated with varying amounts of test compounds for 2 hours at 37°C and then stimulated with F(ab')2 goat anti-human IgM (5 µg/ml) (Invitrogen) for 17 minutes in a 37°C water bath. Cells are spun at 4°C with centrifugation and whole cell extracts are prepared using 300 µl lysis buffer (Cell Signaling Technology, Danvers, MA, USA). The resulting lysates are sonicated and the supernatants are collected. The level of Akt phosphorylation in the supernatants is analyzed using PathScan phosho-Akt1 (Ser473) sandwich ELISA kits (Cell Signaling Technology) according to the manufacturer's instructions.

[00360] Various modifications of the invention, in addition to those shown herein, will be apparent to those skilled in the art from the aforementioned description. Such modifications are intended to fall within the scope of the appended claims. Each reference, including all patents, patent applications and publications, cited in this application is incorporated herein by reference in its entirety.

Claims (23)

1. Salt, characterized in that it is (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloric acid salt, which is crystalline, showing at least four XRPD peaks, in terms of 2-theta, selected from 11.3° ± 0.2°, 16.4° ± 0.2°, 21.0° ± 0.2°, 23.0° ± 0.2°, 28.1° ± 0.2°, 31.2° ± 0.2° and 32.8° ± 0.2°. 2. Salt, according to claim 1, characterized in that it is a stoichiometric ratio of 1:1 between (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one and hydrochloric acid. 3. Salt, according to claim 1 or 2, characterized in that it presents a DSC thermogram having an endothermic peak at 207 ± 3°C. 4. Salt, according to claim 1 or 2, characterized in that it has a DSC thermogram as shown in Figure 1. 5. Salt, according to any one of claims 1 to 4, characterized in that it has a TGA thermogram as shown in Figure 2. 6. Salt, according to any one of claims 1 to 5, characterized in that it has at least five peaks of XRPD, in terms of 2-theta, selected from 11.3° ± 0.2°, 16.4° ± 0.2°, 21.0° ± 0.2°, 23.0° ± 0.2°, 28.1° ± 0.2°, 31.2° ± 0.2° and 32.8° ± 0.2°. 7. Salt, according to any one of claims 1 to 5, characterized in that it has an XRPD profile as shown in Figure 3. 8. Pharmaceutical composition, characterized in that it comprises a salt, as defined in any one of claims 1 to 7, and a pharmaceutically acceptable vehicle. 9. Method of inhibiting an activity of a PI3K kinase, in vitro, characterized in that it comprises placing the kinase in contact with a salt, as defined in any one of claims 1 to 7. 10. Salt, according to any one of claims 1 to 7, characterized in that it is for use in treating a disease in a patient, wherein said disease is selected from idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, autoimmune hemolytic anemia (AIHA), membranous nephropathy, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), hairy cell leukemia, mantle cell lymphoma, Burkitt's lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasma lymphoma, extranodal marginal zone lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, mucosal associated lymphoma (MALT), B-cell lymphoma, lymphoma mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (also known as asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), and B-cell lymphoma; or the disease is idiopathic thrombocytopenic purpura (ITP) selected from relapsed ITP and refractory ITP; or the disease is vasculitis selected from Behçet's disease, Cogan's syndrome, giant cell arthritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemic vasculitis (hepatitis C virus (HPC) or essential) Henoch-Schonlein (HSP), hypersensitive vasculitis, microscopic polyangiitis, Wegener's granulomatosis and systemic vasculitis (AASV) associated with antineutrophil cytoplasmic antibody (ANCA); or the disease is non-Hodgkin's lymphoma (NHL) selected from relapsed NHL, refractory NHL, and recurrent follicular NHL; or the disease is B-cell lymphoma, wherein said B-cell lymphoma is diffuse large B-cell lymphoma (DLBCL); or the disease is B-cell lymphoma, wherein said B-cell lymphoma is diffuse large B-cell lymphoma of the B-cell activated type (ABC) or diffuse large B-cell lymphoma of central germinal B-cell (GBC); or the disease is osteoarthritis, restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, inflammation, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, or Sjogren's syndrome; or the disease is rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus, or inflammation related to any of the above; or the disease is systemic lupus erythematosus or lupus nephritis; or the disease is breast cancer, prostate cancer, colon cancer, endometrial cancer, brain cancer, bladder cancer, skin cancer, uterine cancer, ovarian cancer, lung cancer, pancreatic cancer, kidney cancer, gastric cancer or a hematological cancer; or the disease is a hematologic cancer that is acute myeloblastic leukemia or chronic myeloid leukemia; or the illness is acute lung injury (ALI) or adult respiratory distress syndrome (ARDS). 11. Salt, according to any one of claims 1 to 7, characterized in that it is for use in the treatment of follicular lymphoma in a patient. 12. Salt according to any one of claims 1 to 7, characterized in that it is for use in treating marginal zone lymphoma in a patient. 13. Salt according to any one of claims 1 to 7, characterized in that it is for use in treating mantle cell lymphoma in a patient. 14. Salt, according to any one of claims 1 to 7, characterized in that it is for use in the treatment of myelofibrosis in a patient. 15. Salt preparation process, as defined in any one of claims 1 to 7, characterized in that it comprises reacting a compound of Formula I: with hydrochloric acid to form said salt. 16. Process according to claim 15, characterized in that said hydrochloric acid is 1 M aqueous hydrochloric acid. 17. Process according to claim 15 or 16, characterized in that said reaction is carried out at a temperature of 45°C to 55°C. 18. Process according to any one of claims 15 to 17, characterized in that the process comprises: adding hydrochloric acid to the compound of Formula I at room temperature to form an aqueous paste; heating said aqueous slurry to a temperature of from 45°C to 55°C to form a solution; and cooling the solution to a temperature of 0°C to 5°C to crystallize said salt. 19. Use of a salt, as defined in any one of claims 1 to 7, characterized in that it is for preparing a composition or medicine for the treatment of a selected disease of idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, autoimmune hemolytic anemia (AIHA), membranous nephropathy, chronic lymphocytic leukemia (CLL), lymphoma non-Hodgkin's lymphoma (NHL), hairy cell leukemia, mantle cell lymphoma, Burkitt's lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasmic lymphoma, extranodal marginal zone lymphoma, Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, mucosal associated lymphoma (MALT), B-cell lymphoma, cell lymphoma Mediastinal (thymic) large B, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smoldering myeloma (also known as asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), and B-cell lymphoma; or the disease is idiopathic thrombocytopenic purpura (ITP) selected from relapsed ITP and refractory ITP; or the disease is vasculitis selected from Behçet's disease, Cogan's syndrome, giant cell arthritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemic vasculitis (hepatitis C virus (HPC) or essential) Henoch-Schonlein (HSP), hypersensitive vasculitis, microscopic polyangiitis, Wegener's granulomatosis and systemic vasculitis (AASV) associated with antineutrophil cytoplasmic antibody (ANCA); or the disease is non-Hodgkin's lymphoma (NHL) selected from relapsed NHL, refractory NHL, and recurrent follicular NHL; or the disease is B-cell lymphoma, wherein said B-cell lymphoma is diffuse large B-cell lymphoma (DLBCL); or the disease is B-cell lymphoma, wherein said B-cell lymphoma is diffuse large B-cell lymphoma of the B-cell activated type (ABC) or diffuse large B-cell lymphoma of central germinal B-cell (GBC); or the disease is osteoarthritis, restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, inflammation, angiogenesis, pancreatitis, kidney disease, inflammatory bowel disease, myasthenia gravis, multiple sclerosis, or Sjogren's syndrome; or the disease is rheumatoid arthritis, allergy, asthma, glomerulonephritis, lupus, or inflammation related to any of the above; or the disease is systemic lupus erythematosus or lupus nephritis; or the disease is breast cancer, prostate cancer, colon cancer, endometrial cancer, brain cancer, bladder cancer, skin cancer, uterine cancer, ovarian cancer, lung cancer, pancreatic cancer, kidney cancer, gastric cancer or a hematologic cancer; or the disease is a hematologic cancer that is acute myeloblastic leukemia or chronic myeloid leukemia; or the illness is acute lung injury (ALI) or adult respiratory distress syndrome (ARDS). 20. Use of a salt, as defined in any one of claims 1 to 7, characterized in that it is for preparing a composition or medicine for the treatment of follicular lymphoma in a patient. 21. Use of a salt, as defined in any one of claims 1 to 7, characterized in that it is for preparing a composition or medicine for the treatment of marginal zone lymphoma in a patient. 22. Use of a salt, as defined in any one of claims 1 to 7, characterized in that it is for preparing a composition or medicine for the treatment of mantle cell lymphoma in a patient. 23. Use of a salt, as defined in any one of claims 1 to 7, characterized in that it is for preparing a composition or medicine for the treatment of myelofibrosis in a patient.